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Abstract 
Urinary dysfunction is a very common and one of the most debilitating consequences of 
spinal cord injury (SCI), being in the top list of treatment priorities. The direct damage to central 
nerves implicated in the control of lower urinary tract (LUT) lead to bladder areflexia and voiding 
deficiency that is subsequently overcome by neurogenic detrusor overactivity (NDO). This 
condition affects nearly 90% of SCI patients and is characterized by periods of extremely high 
intravesical pressures, which compromise kidneys’ integrity, and frequent episodes of urinary 
incontinence that strongly affect their quality of life. Thus, management of NDO is of foremost 
importance and still a clinical challenge. 
 Botulinum toxin A (BoNT/A) is a powerful tool in the management of hyperactive 
muscles and is currently the gold standard treatment for NDO, for patients who are refractory 
to antimuscarinics, the first line of therapy. Numerous studies support the efficacy of bladder 
wall injections of BoNT/A in reducing bladder pressure and episodes of urinary incontinence. 
BoNT/A therapeutic effects last for several months and produce tremendous positive impact in 
patients’ quality of life. However, severe urinary retention is still commonly pointed as an 
adversity of the treatment that needs to be overcome. In Publications I and II included in this 
dissertation we addressed that issue and conducted research aiming to improve BoNT/A-based 
treatment strategies. 
 In Publication I we defined an accurate conversion ratio for bladder-wall administration 
of the two BoNT/A formulations mostly used in clinics, onabotulinumtoxin/A (Onabot/A) and 
abobotulinumtoxin/A (Abobot/A). Onabot/A has been particularly well studied and it is the 
unique toxin product licensed for the treatment of NDO. Thus, doses of Abobot/A used in clinical 
urology are inaccurately established based on unspecific conversion ratios. With a fine analysis 
of toxin catalytic activity on SNAP-25, the specific target of the toxin, in bladders of mice 
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receiving each one of the formulations, we established a proper comparison and concluded that 
1 unit (U) of Onabot/A is equivalent to 1.6 U of Abobot/A. 
 In Publication II we tested if intrathecal administration of BoNT/A, which restricts the 
toxin effect to the central processes of bladder sensory afferents, can be used to improved 
urinary dysfunction following SCI. This approach resulted in impairment of bladder afferents, 
implicated in NDO emergence and maintenance, and significant improvements in urodynamics, 
without affecting parasympathetic bladder innervation. These results support that restricting 
the action of the toxin to the sensory innervation of the bladder is still effective in improving 
bladder function without causing urinary retention. 
 As prevention is always better than cure, we placed additional efforts in studying 
possibilities to prevent NDO with neurotoxins-based treatments initiating early after SCI. We 
tested if bladder injections of BoNT/A during spinal shock were capable of modulate the 
emergence of bladder dysfunction (unpublished observations). We failed to find significant 
urodynamic improvements after early treatment with BoNT/A, in line to absence of toxin-
mediated effects in bladder innervation and central neuronal projections. This most probably 
reflects incapacity of affected silent neurons to internalize the toxin. 
In Publication III, we tested if intravesical resiniferatoxin (RTX) is effective in NDO 
prevention. RTX is a strong desensitizing agent of the TRPV1 channel, upregulated in the bladder 
of NDO patients and contributing to its pathophysiology. We found that the early treatment with 
RTX lead to significant urodynamic improvements, with decreased frequency of bladder 
contractions and marked reduction of intravesical pressures. These beneficial treatment 
outcomes resulted from bladder TRPV1 desensitization and consequent modulation of nerve 
sprouting. Effects were restricted to the bladder and support the use of RTX at early stages of 
disease progression to prevent degradation of urinary function. 
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Resumo 
A disfunção urinária é uma das mais comuns e debilitantes consequências das lesões 
medulares, ocupando um lugar de topo na lista das prioridades de tratamento. O dano direto 
nas vias neuronais do sistema nervoso central implicadas no controlo do trato urinário inferior 
resulta numa situação de areflexia da bexiga, e consequente perda da capacidade urinária, que, 
subsequentemente, dá lugar à condição de hiperactividade neuronénica do detrusor (NDO). 
Esta patologia afeta cerca de 90% dos indivíduos que vivem com uma lesão medular e 
caracteriza-se por períodos de pressões intravesicais extremamente elevadas, que 
comprometem a integridade renal, e por episódios frequentes de incontinência urinária que 
afetam severamente a qualidade de vida dos doentes. Assim, o tratamento da NDO é de extrema 
importância e continua a ser um desafio para a prática clínica. 
A toxina botulínica do tipo A (BoNT/A) é uma ferramenta poderosa no tratamento da 
hiperatividade muscular e é atualmente o tratamento de excelência da NDO em doentes que 
não respondem à terapia de primeira linha com antimuscarínicos. Até à data, são múltiplos os 
estudos que demonstram a eficácia de injeções de BoNT/A na parede da bexiga na redução da 
pressão intravesical e no número de episódios de incontinência urinária. Os efeitos terapêuticos 
da toxina são extraordinariamente duradouros e têm um impacto muito significativo na 
melhoria da qualidade de vida dos doentes. Contudo, a retenção urinária que advém da 
administração da BoNT/A permanece um problema que é necessário ultrapassar. Com foco 
nessas questões, os trabalhos que constam das Publicações I e II incluídas na presente 
dissertação foram desenvolvidos com o objetivo de melhorar as estratégias terapêuticas que se 
baseiam na utilização da BoNT/A. 
Na Publicação I definiu-se um fator de conversão de doses concreto para a injeções na 
bexiga das duas formulações de BoNT/A maioritariamente utilizadas na clinica, 
onabotulinumtoxin/A (Onabot/A) e abobotulinumtoxin/A (Abobot/A). A Onabot/A tem vindo a 
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ser particularmente estudada e é a única formulação que se encontra aprovada por autoridades 
competentes no tratamento da NDO. Consequentemente, as doses de Abobot/A utilizadas na 
prática clínica baseiam-se em fatores de conversão aproximados e inespecíficos. Com base na 
fina análise da atividade catalítica da toxina no seu alvo específico, a proteína SNAP-25, em 
bexigas de murganhos tratados com cada uma das formulações estabeleceu-se um fator de 
comparação concreto e concluiu-se que 1 unidade de Onabot/A corresponde a 1.6 unidades de 
Abobot/A. 
Na Publicação II estudou-se se a restrição do efeito da BoNT/A aos ramos centrais dos 
aferentes da bexiga, através de administração por via intratecal, resultava na melhoria da 
disfunção urinária que decorre de lesão medular. Esta abordagem levou à modulação dos 
aferentes vesicais, que estão implicados no aparecimento e manutenção da NDO, e resultou em 
melhorias significativas do padrão urodinâmico, sem afetar a inervação parassimpática da 
bexiga. Estes resultados sustentam a ideia de que a restrição da atividade da toxina à inervação 
sensitiva da bexiga é eficaz na melhoria da função vesical sem risco de ocorrência de retenção 
urinária associada. 
Porque a prevenção é sempre melhor do que a cura, colocaram-se esforços adicionais 
no estudo de possibilidades de prevenir o aparecimento de NDO com recurso a tratamentos 
com neurotoxinas numa fase precoce pós-lesão. Inicialmente testou-se se a administração de 
BoNT/A na bexiga durante a fase de choque espinhal levava à modulação do aparecimento da 
disfunção urinária (observações não publicadas). O tratamento precoce com a toxina não 
resultou em alterações urodinâmicas significativas, o que se relacionou com a ausência de 
qualquer efeito na inervação da bexiga e nas respetivas projeções centrais desses neurónios. 
Estas observações refletem, muito provavelmente, a incapacidade de neurónios silenciados, 
afetados pela lesão, internalizarem a toxina. 
Na Publicação III testou-se se a administração intravesical da resiniferatoxina (RTX) era 
eficaz na prevenção da NDO. A RTX é um potente agente dessensibilizador do recetor TRPV1, 
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que se sabe ter expressão aumentada na bexiga de doentes com NDO, contribuindo para a sua 
patofisiologia. Concluiu-se que o tratamento precoce com RTX resulta na melhoria significativa 
da função urodinâmica, levando ao decréscimo do número de contrações da bexiga e à redução 
significativa das pressões intravesicais. Estes efeitos resultam da dessensibilização do recetor 
TRPV1 e da consequente modulação do crescimento neuronal, exclusivamente ao nível da 
bexiga, e sustentam o uso da RTX em fases iniciais da progressão da doença, no sentido de 
prevenir a deterioração da função vesical. 
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The complexity of the nervous system reflects its ability to control all and each part of 
the body. Control of lower urinary tract (LUT) function depends on complex neuronal pathways, 
easily jeopardized by spinal cord injury (SCI). Because it interrupts neuronal network regulating 
LUT function, SCI frequently leads to urinary dysfunction, a major concern for SCI patients. 
Treatment is often unsatisfactory and a major goal of the present work was to pave the way for 
improving available treatments and also investigate the possibility to harness NDO emergence. 
1. Neuronal pathways innervating the lower urinary tract
The LUT comprises the urinary bladder, a reservoir for urine storage, and an outlet 
structure, including bladder neck, urethra and striated muscles of the external urethral sphincter 
(EUS), which contract and relax to block or permit voiding [1]. In newborns, urine release is a 
reflexive process, exclusively dependent on a primitive lumbosacral neuronal pathway [2]. 
Voluntary control of micturition develops with the maturation of the central nervous system and 
depends on learned behaviour, acquired in early childhood [2]. In adults, voluntary switching 
between storage and voiding relies on the synchronised contraction and relaxation of bladder 
and outlet structures. This coordination is only achieved via activation of intricate neuronal 
pathways, involving peripheral and centrally located neurons [3, 4]. 
In Humans and experimental animals, the LUT is innervated by autonomic sympathetic 
and parasympathetic nerves, as well as somatic motor and sensory fibres [3, 4]. Sympathetic 
noradrenergic fibres originate in thoracolumbar segments of the spinal cord, run through the 
inferior mesenteric plexus and hypogastric nerve and induce bladder relaxation via activation of 
β3 receptors [5]. These receptors are expressed by bladder smooth muscle cells [6] and 
acetylcholine‐containing nerve fibres [7]. Sympathetic fibres also run through paravertebral 
chain, enter pelvic nerves to reach the bladder neck and urethra. These fibres, exerting their 
effect via α1 receptors, are apposed to the smooth muscle fibres of the internal urethral 
sphincter [5]. Parasympathetic preganglionic fibres arise from neurons located in sacral spinal 
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segments and run through sacral roots and pelvic nerves, reaching post‐ganglionic neurons, 
which are positioned intramurally in the Human bladder. Axons emerging from neurons located 
in these ganglia innervate the detrusor muscle. Both preganglionic and postganglionic neurones 
release acetylcholine, which activate nicotinic receptors in postganglionic neurons and 
muscarinic receptors in bladder smooth muscle cells [5, 8]. The urethra is also innervated by 
postganglionic nerves, which release nitric oxide (NO) to induce relaxation [3, 9]. Finally, somatic 
cholinergic motor nerves that originate in sacral spinal cord segments travel through pudendal 
nerves, contributing to urethral contraction through activation of EUS nicotinic receptors [1, 10]. 
While efferent fibres regulate the cycles of contraction/relaxation necessary for proper 
LUT function, afferent neurons sense bladder stretch. Their cell bodies are located in 
lumbosacral dorsal root ganglia (DRG) and they convey neuronal inputs from the LUT to second 
order neurons located in the spinal cord [1, 11]. This sensory input reaches the thoracolumbar 
spinal cord carried by afferents travelling in the hypogastric nerve and the lumbosacral segments 
of the spinal cord, via the pelvic nerve. Bladder sensory afferents are glutamatergic [12‐14] and 
can be categorized into Aδ and C‐fibres. Aδ afferents have small‐sized but larger cell bodies than 
C‐fibres and their processes are covered by a thin myelin sheath resulting in higher conduction 
velocity [15, 16]. These afferents respond to physiological bladder filling, such as passive 
bladder‐wall distention and active detrusor contractions [17]. C‐fibres have small sized cell 
bodies and their axons are unmyelinated. The majority of them are peptidergic, expressing 
substance P (SP), calcitonin‐gene related peptide (CGRP) and pituitary adenylate cyclase 
activating polypeptide (PACAP). In addition, these peptidergic fibres also express numerous 
receptors, including transient receptor potential vanilloid 1 (TRPV1), tropomyosin receptor 
kinase A (TrkA) and B (TrkB), the high affinity receptors for nerve growth factor (NGF) and brain‐
derived neurotrophic factor (BDNF), respectively, and purinergic receptors [18]. While in normal 
conditions C‐fibres have minor contribution, they have an important and well‐established role 
in the pathophysiology of multiple LUT syndromes, such as urinary dysfunction arising from SCI. 
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1.1. Neuronal control of urine storage and voiding 
The LUT operates in a switch‐like fashion, without intermediate stages between voiding 
and continence. In normal physiological conditions, during storage the bladder undergoes low‐
pressure filling until it retains approximately 300 to 400 mL of urine [19]. During bladder filling, 
intravesical pressures are not high enough to generate a strong sensory input. This low intensity 
sensory firing is conveyed to spinal interneurons and from there to the L‐region of the pontine 
storage centre, located in the pons. During bladder filling, continence results from sympathetic 
stimulation of the smooth muscle of bladder neck and urethra, through the hypogastric nerve, 
and somatic activation of the EUS via pudendal nerves, which keeps the outlet contracted to 
avoid urine leakage [1] (Figure 1a).  
When bladder reaches its maximal capacity, bladder afferents are activated and a high 
intensity sensory input is generated, which is conveyed to the spinal cord and supraspinal 
structures, including the cortex. Once a decision to void is made, the pontine micturition centre 
(PMC) is activated. Its descending projections inhibit sympathetic and somatic urethral 
innervation, inducing relaxation of the urethral sphincter. In turn, preganglionic 
parasympathetic neurons at sacral spinal cord are stimulated, generating parasympathetic 
outflow to induce detrusor contraction and urine release (Figure 1b). Of note, in healthy 
individuals, micturition is under voluntary control, which require activation of important 
supraspinal nuclei. Accordingly, the activation of the cingulate gyrus and insula has been 
reported following perception of bladder volume [20]. Those areas are known to indirectly 
modulate PMC processing via the periaqueductal gray matter (PAG) [1]. Thus, when voiding is 
appropriate, the prefrontal cortex interrupts the tonic suppression of PAG input to the PMC. 
This leads to interruption of the sympathetic input to the detrusor and parasympathetic drive 
to the urethral sphincter, resulting in bladder contraction and urethral relaxation, necessary for 
urine expulsion.  
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 Figure 1 – Neuronal pathways implicated in urine storage (a) and voiding (b). Sympathetic efferent and 
sensory afferent innervation from the spinal cord to bladder and urethra is depicted in red. 
Spinobulbospinal reflex pathways are represented in blue. Parasympathetic outflow to the bladder is 
depicted in green. Fowler et al., 2008 [1]. 
 
2. Spinal cord injury and urinary dysfunction 
2.1. Prevalence, causes and consequences of spinal cord injuries 
SCI is a devastating event with a tremendous impact in patients’ life. It is currently 
estimated that more than 2 million people worldwide live with SCI and World Health 
Organization projects 40 to 80 new cases per millions of people every year [21, 22]. Non‐
traumatic events such as spinal stenosis, tumours, vascular ischemia and congenital diseases 
may lead to SCI. However, traumatic injuries related to motor vehicle accidents, falls, sports and 
violence are the most common causes [23, 24]. SCI represents an enormous burden to 
individuals and overall economy [25]. Although improved medical treatment has greatly 
increased post‐injury survival, patients present high rates of incapacity and need costly daily 
care support [22, 26]. 
32
The majority of spinal lesions are incomplete and occur at cervical levels of the cord [22], 
causing a disruption of neuronal pathways that control multiple body systems. For that reason, 
SCI is typically associated with substantial impairment or complete loss of motor, sensory and 
autonomic functions. Among all consequences, LUT dysfunction is one of the most prevalent, 
affecting nearly 90% of patients and severely compromising their quality of life. Accordingly, it 
is often referred by patients as one of the most incapacitating aspects in post‐injury everyday 
life [27‐29]. Management of urinary dysfunction is fundamental in early and late stages post‐
injury, as it might result in serious complications such as life‐threatening kidney failure and 
frequent urinary infections. In addition, LUT dysfunction also has a tremendous impact on social 
life, either because patients fear the occurrence of episodes of urinary incontinence or due to 
the permanent need of being close to a toilet room [30]. 
While during spinal shock disruption of LUT parasympathetic outflow leads to bladder 
hypocontractility, disease progression often results in bladder hyperactivity [3]. It is estimated 
that nearly 95% of SCI patients develop neurogenic detrusor overactivity (NDO), a pathological 
condition characterized by strong and frequent bladder contractions detected in urodynamic 
evaluations [31‐34], accompanied by frequent episodes of urinary incontinence (UI) that deeply 
influence their everyday life . Moreover, due to the loss of coordination between bladder and 
EUS, known as detrusor sphincter dyssynergia (DSD), patients experience periods of very high 
and extremely dangerous intravesical pressures that produces significant damage to the upper 
urinary tract. Therefore, treatment of SCI‐induced urinary dysfunction is of foremost 
importance, topping the list of priorities for patients and caregivers and remaining a major 
challenge in rehabilitation units. 
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2.2. Mechanisms underlying neurogenic detrusor overactivity and detrusor-sphincter 
dyssynergia 
Spinal injury above lumbosacral levels acutely disrupts voluntary voiding and 
supraspinal LUT control. Loss of descending inputs from supraspinal regulatory centres triggers 
bladder areflexia and continuous urine storage [35]. With time, the majority of patients regain 
automatic voiding capacity, which is linked to NDO and DSD emergence [36] (Figure 2). 
Figure 2 – Schematic representation of lower urinary tract innervation in a normal situation (a) and after 
a spinal cord injury above lumbosacral segments (b).  Adapted from Wyndaele et al., 2016 [36]. 
The reasons underlying the development of such conditions have been extensively 
studied and loss of bulbospinal inhibitory inputs, synaptic rearrangement, axonal growth, 
changes in neurotransmitter pharmacology and modifications in afferent firing patterns are 
thought to concur in NDO and DSD development and maintenance [37‐39]. These processes are 
dependent on the effects of neurotrophins, including NGF and BDNF, on the neuronal circuits 
governing LUT function [40‐42]. 
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Because of such neuroplastic events, a new micturition reflex is established, exclusively 
mediated by type C unmyelinated bladder afferents [43‐46] (Figure 3). The involvement and 
importance of C fibres is further strengthened by clinical trials demonstrating that 
desensitization of TRPV1 expressing fibres markedly reduced NDO [47‐50].  
 
 
Figure 3 ‐ Schematic representation of the afferent pathways conveying neuronal inputs from the bladder 
to the supraspinal regulatory centres (Red boxes and black arrows) and the micturition reflex circuitry 
that emerges after spinal cord injury (Green boxes and grey arrows). Fowler et al., 2008 [1]. 
 
2.3. Management of bladder dysfunction after spinal cord injury  
With marked improvements in survival of traumatic SCI patients [51], dealing with 
urinary dysfunction became an important priority. During spinal shock, the main concern is to 
prevent the rise of intravesical pressures and protect the upper urinary tract [36, 52]. Once NDO 
and DSD are installed, treatment aims to prevent urine leakage [34, 36]. For that, several 
approaches are available to reduce detrusor contractions and improve urine storage. These are 
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combined with intermittent catheterization, performed by the caregiver or the patient, for 
timely urine removal. However, available treatments are not exempt of bothersome secondary 
effects, including urinary retention and urinary tract infections [30]. 
NDO management is typically initiated with antimuscarinics, including oxybutynin, 
fesoterodine and darifenacin, aiming to reduce bladder hypercontractility [30, 36]. These drug 
block M2 and M3 muscarinic receptors, present in the detrusor muscle, and prevent 
acetylcholine‐mediated detrusor contractility. However, anticholinergic medication is often 
associated with severe adverse effects, such as cognitive impairment, constipation, dry mouth, 
blurred vision and tachycardia, leading patients to discontinue treatments. Desmopressin, a 
vasopressin analogue, might also be useful as a therapeutic option due to its effectiveness in 
reducing urine production [36, 53]. More recently, agonists of β3 adrenoreceptors were licensed 
for the treatment of overactive bladder [54, 55]. While some investigators demonstrated 
improvement of urodynamic parameters in SCI patients and animals treated with a combination 
of antimuscarinic drugs with β3 agonists [56, 57], other studies failed to show significant benefits 
[58]. Sacral and tibial neuromodulation as well as electrical stimulation of the pudendal and 
dorsal genital nerves have also emerged as valuable therapeutic options for neurogenic bladder, 
with long‐lasting effects [30, 59], but the underlying molecular mechanisms of neuromodulation 
are still poorly understood. 
2.3.1. Neurotoxins in the treatment of bladder dysfunction after spinal cord injury 
a) Botulinum toxin A (BoNT/A)
Bladder wall injections of BoNT/A is the current gold standard therapy for NDO patients 
that are refractory to first line treatments [30, 52]. By effectively blocking vesicle‐mediated 
neurotransmission, this toxin leads to flaccid paralysis of bladder smooth muscle [60, 61]. The 
success of this treatment can be ascribed to its long‐lasting effects, safe administration 
technique and lack of considerable adverse effects [61]. 
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The mechanism of action of BoNT/A was firstly described for the neuromuscular 
junction (NMJ) [62, 63]. Composed by two peptide chains, a heavy and a light chain (HC and LC, 
respectively), this toxin is internalized by active axonal terminals. The HC binds to ganglioside 
receptors at the surface of presynaptic neurons, allowing docking of the neurotoxin to the 
presynaptic terminal. During neurotransmission, the synaptic vesicle glycoprotein 2A (SV2) is 
exposed and the toxin binds specifically to this protein [64]. As the synaptic vesicle is recycled, 
BoNT/A is internalized and the LC is released from the HC, acquiring proteolytic activity. The LC 
cleaves proteins necessary for docking and fusion of neurotransmitter‐containing vesicles, 
including vesicle‐associated membrane protein (VAMP) or synaptobrevin, syntaxin and 
synaptosomal nerve‐associated protein of 25 kDa (SNAP‐25) (Figure 4). In skeletal muscle, the 
blockade of neurotransmission of cholinergic fibres results in paralysis. Pioneer studies dating 
back to the 1980’s showed that injections of the neurotoxin into hyperactive muscles induced 
site‐limited temporary relaxation [65‐67]. The restricted activity to the injection site, the low 
frequency of adverse effects and the long‐duration in neuromuscular blockade support its 
therapeutic use in multiple spasmodic, painful and hypersecretory syndromes [68‐70]. 
Figure 4 ‐ Schematic representation of botulinum toxin internalization (1) in a presynaptic neuron through 
vesicle recycling (2) and subsequent events of neuronal intoxication, such as protoxin cleavage and light 
chain translocation to the cytosol (3) culminating in the cleavage of SNARE proteins (4). Adapted from 
Rossetto et al., 2014 [71]. 
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BoNT/A is currently available in three distinct formulations, OnabotulinumtoxinA 
(Onabot/A), AbobotulinumtoxinA (Abobot/A) and IncobotulinumtoxinA (Incobot/A), 
commercialized with the trade names of Botox© (Allergan, Inc., Irvine, CA, USA), Dysport© 
(Ipsen Biopharm Ltd., Wrexham, UK) and Xeomin© (Merz PharmaceuticalsGmbH, Frankfurt, 
Germany), respectively. All formulations share the same active principle, consisting of the 150 
kDa neurotoxin, but differ in their content on accessory proteins [70]. The efficacy of each 
formulation is thought to depend on the respective diffusion across the treated tissue and 
unitary doses are not interchangeable, making it difficult to establish a conversion ratio [72]. 
Therefore, accurate therapeutic dosages of each formulation should be carefully evaluated in 
the context of each application [70]. 
Botulinum toxin A in Neuro-urology 
The initial works supporting the use of BoNT/A in SCI‐related LUT dysfunction date from 
more than 20 years ago [73‐75]. The pioneer studies by Schurch and co‐workers demonstrated 
that injections of BoNT/A in the EUS alleviated DSD in chronic SCI patients, with improvements 
in post void residual volumes that were still present 3 to 9 months post‐injections [74, 75]. The 
same research team also demonstrated significant improvements in urodynamics as well as 
decrease in urinary incontinence episodes after BoNT/A bladder‐wall injections [76, 77]. Large, 
double‐bind placebo‐controlled studies were performed later and found a significant reduction 
in episodes of urinary incontinence and clear improvements in urodynamic parameters, such as 
detrusor compliance, bladder capacity and maximum voiding pressures [78‐80]. Improvement 
of LUT function was long‐lasting and markedly improved patients’ quality of life. At the present, 
only the formulation Onabot/A has been approved by competent authorities for the treatment 
of NDO [72, 81]. 
In the bladder of humans and experimental animals, the targets of BoNT/A include 
parasympathetic cholinergic, sympathetic adrenergic and sensory peptidergic fibres [82‐84]. 
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This explains not only its impact on reducing bladder contractions but also its antinociceptive 
effects [85‐87]. In fact, improvement of bladder function and pain reflect a decrease in CGRP 
release from bladder afferents [88], as well as a reduction in the expression of P2X3 and TRPV1 
receptors in bladder fibres [89] and the blockade of neurotransmitters release from sensory 
fibres [60, 90] (Figure 5).  
 
 
Figure 5: Sensory effects of BoNT/A. (A) Accumulation of the toxin in the urothelium (1) and inhibition of 
ATP release in the bladder (2) followed by internalization and retrograde axonal transport through bladder 
sensory afferents (3). (B) Bladder administration of BoNT/A diminishes the release of neuropeptides by 
afferent terminals and modulates NGF and TRPV1 expression in the bladder and lumbosacral spinal cord. 
Adapted from Jiang el al., 2015 [85]. 
 
Although debatable, some researchers suggest that BoNT/A activity is not restricted to 
the injection site and hypothesize that the neurotoxin is transported and acts at distant 
locations, carried via blood flow or axonal transport [91]. Accordingly, the presence of cleaved 
SNAP‐25, an established marker of BoNT/A activity [82], was detected in retina, fascial nucleus, 
superior colliculus and bladder‐wall after being administered in the optic tectum, whisker 
muscles, eye and lumbosacral intrathecal space, respectively, supporting that BoNT/A can 
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undergo retrograde and anterograde transport [92‐95]. Therefore, some authors suggest that 
the pronounced efficacy of BoNT/A administration relies not only on its peripheral but also on 
central effects [96]. 
b) Resiniferatoxin
Resiniferatoxin (RTX) belongs to a family of compounds known as vanilloids. This family 
of molecules includes capsaicin, the pungent extract obtained from capsicum peppers. Like 
capsaicin, RTX is an agonist of the TRPV1 receptor [97]. This ion channel is a polimodal receptor 
[98, 99] present in bladder afferents and urothelial cells [100‐102]. TRPV1 activation by 
intravesical administration of vanilloids, including RTX and capsaicin, results in long‐lasting 
desensitization of bladder afferents [101, 103] (Figure 6). 
Figure 6: Prior desensitization of TRPV1 expressing fibres provoked by a short contact with channel 
agonists (a) and later effects producing profound changes in such fibres resulting from the prolonged 
administration of TRPV1 agonists (b). Adapted from Deruyver et al, 2015 [104]. 
In comparison to capsaicin, RTX‐induced TRPV1 desensitization is more pronounced and 
effective, but surprisingly, treatment is less painful. Indeed, capsaicin has also been used to 
desensitize bladder sensory afferents [48, 105], but the pungency of its solutions has hampered 
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its clinical application, with clinicians preferring RTX. Because it has a higher affinity for TRPV1, 
RTX can be used in nanomolar concentrations without causing any burning sensation [106]. 
Resiniferatoxin in Neuro-urology 
Capsaicin was initially intravesically applied in patients with bladder pain, detrusor 
hyperreflexia and neurogenic bladder [47, 48, 106‐108] but its use was discontinued due to its 
highly irritant properties. In subsequent studies, RTX was preferred as it is more potent and less 
pungent than capsaicin [105, 109]. In patients presenting bladder hyperreflexia due to CNS 
pathology or insult, intravesical RTX, used in concentrations of 50 to 100 nmol/L, resulted in 
marked improvements in urinary symptoms [110]. Lazerri et al. also showed significant 
improvements in bladder capacity, frequency, nocturia and incontinence in patients diagnosed 
with bladder hyperactivity, which were still evident 4 weeks after treatment [111].  In both 
studies, treatment was not considered painful, with patients only referring minor itching and 
mild discomfort during RTX administration. In animals, instillation of 100nM of RTX in rats’ 
bladders resulted in effective bladder afferent desensitization without significant increase in 
spinal c‐Fos, a well‐defined marker of noxious input [112]. Several other studies supported the 
clinical use of intravesical RTX, particularly in patients with NDO caused by spinal cord injury and 
multiple sclerosis, with improvement of bladder function and increased protection of the upper 
urinary tract [49, 50, 106, 113]. Similar observations were obtained from patients with idiopathic 
detrusor overactivity [114]. Still it was not possible to produce a stable and affordable 
formulation and with an upraise of BoNT/A as the treatment of choice for NDO, RTX is now 
seldom used [115]. 
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Main goals 
From the review above, it is clear that several therapeutic tools for NDO management 
have been developed over the years. Treatment is usually initiated with anticholinergic drugs, 
aiming to block detrusor contractions and making the bladder a flaccid reservoir to be 
periodically emptied by catheterization. For patients refractory to anticholinergics, BoNT/A has 
emerged as an excellent therapeutic choice. Of note, treatments are still not exempt of 
secondary effects and are not fully and/or permanently effective. Also a matter of concern is the 
fact that treatment is only initiated when urinary dysfunction is a fixed condition not likely to 
revert. Still, because prevention is better than cure, some research teams have initiated studies 
aiming to investigate if NDO emergence can be stopped. A recent study showed that 
administration of anticholinergics initiated immediately after SCI helped to hamper NDO 
development [116],  in line with Sievert and co‐workers who used neuromodulation to prevent 
NDO emergence [117]. 
This thesis had two main goals: 
Goal 1: to improve treatment of chronic NDO. 
Specifically, here the objectives were: 
a) To compare the efficacy of two commercially available formulations of
botulinum toxin A, Onabot/A and Abobot/A, and establish an accurate conversion ratio 
for clinical use, (Publication I) 
b) To investigate the effects of intrathecal Onabot/A in NDO treatment
(Publication II) 
Goal 2: to investigate if NDO can be prevented. 
Here, the points addressed were: 
a) To assess if early bladder‐wall injections of Onabot/A modulate NDO
development (unpublished observations) 
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b) To evaluate if early intravesical administration of RTX prevents NDO emergence
(Publication III) 
Data obtained is presented and discussed according to a logical sequence, and not 
necessarily the date of publication. 
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Expression of Cleaved SNAP-25 After Bladder Wall Injection
of OnabotulinumtoxinA or AbobotulinumtoxinA:
A Comparative Study in the Mice
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Aims: Tostudy theexpression of cleavedsynaptosomal associatedprotein of25kDa (cSNAP-25) in thebladderwall injected
withonabotulinumtoxinA(onabotA)orabobotulinumtoxinA (abobotA)andcompare the relativepotencyof these twobrands.
Methods: One injection of 0.5U of onabotA or abobotA diluted in 2ml of saline was carried out in the bladder dome of adult
femalemice,whose bladderswere exposed by laparotomy. Three days later bladderswere collected, divided in five segments
(dome, upper, middle and lower body, and trigone) and each one was sectioned and immunoreacted against cSNAP-25, the
end product of botulinum toxin type A (BoNT/A) activity. From each of the five segments one section was taken at random
and the number of cSNAP-25 immunoreactive (IR) fibers was determined.Results: Each injection resulted in the cleavage
of SNAP-25 in all bladder sections, including those of the more distant segment from the injection point. The average
number of cSNAP-25 positive fibers was higher in the onabotA, 341 301, than in the abobotA-treated mice, 208 152
(P¼0.003). The number of cSNAP-25 IR fibers varied three to five-fold between animals of each experimental group.
Conclusions: These findings confirm that, when injected in the bladder wall, in the same unit amount and same volume,
onabotA is 1.6 times more potent to cleave SNAP-25 than abobotA. The conversion ratio suggested by these experiments is
1:1.6 between onabotA and abobotA. Each injection, although preformed in the same way, may induce substantially
different amounts of cSNAP-25. Neurourol. Urodynam. 36:86–90, 2017. # 2015 Wiley Periodicals, Inc.
Key words: botulinum toxin type A; conversion ratio; cSNAP-25; relative potency; urinary bladder
INTRODUCTION
OnabotA is licensed for the treatment of neurogenic detrusor
overactivity (NDO) and overactive bladder (OAB) in doses of 200
and 100U, respectively.1,2 The approved method for toxin
administration is the bladder wall injection, distributed in 30
points for NDO and 20 points for OAB.3
This new form of drug administration raises two important
questions. One relates to the replicability of the administration
method, as bladder wall injection of BoNT/A clearly depends on
the surgeon’s technique. An incorrect administration may
result in the deposition of the toxin outside the bladder or allow
the backflow of the toxin solution through the injection hole. In
both cases, the amount of toxin available for the impairment of
bladder innervation will decrease, reducing the treatment
efficacy. In fact, from a clinical point of view, this issue is
extremely relevant, as in NDO regulatory trials 25% of patients
did not show a clinically relevant reduction in the number of
incontinence episodes following the first injection.1,4 Also, in
OAB regulatory trials 40% of the patients considered that the
treatment did not improve their urologic condition.5,6 These
percentages are surprising if it is taken into consideration that
the target for BoNT/A is the SNAP-25, a membrane protein
abundantly expressed in all nerve fibers.7 In addition, a recent
subanalysis of NDO trials showed that nonresponders could
have a good outcome to subsequent injections, suggesting that
some variability in drug deliverymay occur during bladderwall
injection.8
Another problem related to bladder injections of BoNT/A is
that, in addition to onabotA, abobotA and incobotulinumtox-
inA (incobotA) are used off-label for the treatment of NDO and
OAB. However, the doses are not interchangeable between
these toxins making a conversion ratio impossible to estab-
lish.9,10 The potency of each brand is established by distinct
tests. Although onabotA potency is determined by the EC50
(amount of toxin required to provoke a response halfway
between the baseline and themaximum response) of cSNAP-25
in differentiated neuroblastoma cells, abobotA potency is
determined by the mouse LD50 (amount of toxin that kills
50% of the mice).11–13 In the urological literature, the empiric
conversion ratio of 1U of onabotA to 3–5U of abobotA is
commonly suggested.14,15 However, accurate comparative
studies necessary to define the appropriate conversion ratio
for bladder wall administration are lacking. Furthermore,
onabotA and abobotA are protein complexes with hemaggluti-
nin being an accessory protein in both cases. OnabotA vials
contain 0.5mg of human albumin and sodium chloride,
whereas abobotA vials contain 0.125mg of human albumin
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and lactose. IncobotA is a nude toxin.10 Themolecularweight of
onabotA, abobotA, and incobotA is 900 kDa, approximately
500 kDa, and 150 kDa, respectively.10,11,15 These differences
may have consequences for the spread of the toxins across the
bladder tissues, which, in turn, may influence the number of
nerve fibers exposed to them at areas of the bladder more
distant from the injection point.
This study has two aims, one primary and one secondary. The
primary aim was to determine the relative potency of the two
most commonly used BoNT/A brands, onabotA and abobotA,
according to the amount of cSNAP-25 expression. The second-
ary aim was to investigate the variations of cSNAP-25
expression between individual animals.
MATERIALS AND METHODS
Animals
All experiments were performed in female C57BL/6J mice
(Charles River, Barcelona, Spain)with an approximateweight of
20–30g, maintained under a 12hr light/12hr dark schedule,
with free access to food and water. All procedures were carried
out according to the European Communities Council Directive
(2010/63/EU) and all efforts were made to reduce the suffering
and the number of animals used.
Reagents and Drugs
Surgeries were performed under isoflurane anesthesia (4%
for induction and 1.5% for maintenance). A sodium pentobar-
bital overdose was used for terminal handling. BoNT/A
formulations, onabotA (trade name: Botox1) and abobotA
(trade name: Dysport1) were purchased from Allergan (Irvine,
CA) and Ipsen Biopharm (Wrexham, UK), respectively. Rabbit
anti-cSNAP-25, produced against the truncated C-terminal
peptide of SNAP-25, was a kind gift from Ornella Rossetto
and has been previously described.16 The avidin–biotin
complex (ABC) was purchased from Vector Labs (Peterborough,
UK). Biotin-conjugated swine anti-rabbit was purchased from
Dakopatt A/5, Dako, Lisbon.
Experimental Groups and Toxin Administration
Twenty-eight mice were anesthetized and their bladders
were exposed bymid-line laparotomy. Bladders weremanually
emptied, to increase the thickness of the bladder wall, and one
single injection was carried out in the bladder dome of each
animal. The injection was performed with a NanoFil 10ml
syringe and a 35G beveled NanoFil needle (World Precision
Instruments, Inc., Hertfordshire, UK). One experimental group
(n¼12) received a single injection of 0.5U of onabotA diluted in
2ml of saline whereas the other group (n¼12) received a single
injection of 0.5U of abobotA diluted in 2ml of saline. Control
animals (n¼4) received a single injection of 2ml of saline. All
the injections were performed by the same investigator, using
the same needle and toxin obtained from one vial from each
brand. After the reconstitution of the toxins with saline, vials
weremaintained at 48C for no longer than 4hr. Three days after
surgery, the expected time for the toxin to exert its maximum
effect on SNAP-25 in rodents,17 animals were euthanized and
their bladders were collected.
Tissue Processing
All bladders were fixed in 4% paraformaldehyde in 0.1M
phosphate buffer for 6 hr, stored overnight in 30% sucrose in
0.1M phosphate buffer and then divided into five segments;
dome, upper, middle and lower body, and trigone. Serial
transverse 20mm sections from each segment were cut in a
cryostat, collected on Superfost Plus slides and stored at
208C until further processing. Detection of cSNAP-25
immunoreactivity was performed by the ABC method.18
Slices were dehydrated with solutions of increased concen-
tration of ethanol, cleared with xylene, mounted with Eukitt,
and coverslipped.
Image and Statistical Analysis
Five randomly collected sections from each bladder segment
(dome, upper,middle and lower body, and trigone; Fig. 1A)were
photographed in a Zeiss Axioscope 40 microscope using the
AxioVision 4.6 software. Using Adobe Photoshop CC software,
images were mounted to create full figures of the five bladder
sections and IR cSNAP-25 fibers were hand drawn and counted.
The entire process was done blindly to the treatment groups.
After counting IR fibers in the 24 animals the mean number of
fibers/section was calculated for each brand and compared
using a t test from the GraphPad Prism software (P< 0.05
statistically significant).
RESULTS
Expression of Cleaved SNAP-25 After OnabotulinumtoxinA or
AbobotulinumtoxinA Administration in the Bladder Wall
Three days after a single injection of 0.5U of onabotA or
abobotA at the top of the bladder dome, cSNAP-25 immunore-
activity was observed in all the sections analyzed from each
bladder segment, dome, upper, middle and lower body, and
trigone (Fig. 1). IR fibers were generally more abundant in
sections obtained from the lower body and trigone (Fig. 1A, C,
andD). Immunoreactionwas observed in themucosa and in the
muscular layers (Fig. 1C and D). In saline injected animals, no
immunoreactivity was observed.
Relative Potency of OnabotulinumtoxinA and
AbobotulinumtoxinA After Administration in the Bladder Wall
The average number of cSNAP-25 IR fibers per section was
341 301 in the group treated with onabotA and 208 152 in
those treated with abobotA (Fig. 2). This difference was
statistically significant (0.003). This suggests that onabotA is
more potent than abobotA, with a conversion ratio of 1U of
onabotA to 1.6U of abobotA.
Variation of the Expression of Cleaved SNAP-25 After
OnabotulinumtoxinA or AbobotulinumtoxinA Administration in
the Bladder Wall
The total number of cSNAP-25 positive fibers/bladder varied
markedly in each experimental group. In the onabotA group,
the four animals with stronger cSNAP-25 immunoreactivity
had a total of 3,065302 positive fibers in the five sections. On
the other hand, the four animals with less labeling had only
578 106 positive fibers in the five bladder sections (Fig. 3A).
This resulted in a fivefold variation between injections. In the
abobotA group, the four animals with stronger IR had
1,628326 and the four animals with lower IR had
502 105 positive nerves, representing a threefold variation
(Fig. 3B).
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Fig. 1. A: Schematic representation of the five sections of the bladder considered for the quantification of cleaved synaptossomal-associated protein of
25 kDa (cSNAP-25). From the top to the bottom there are represented the dome, the upper, middle and lower body, and the trigone sections. B: Distribution
of cSNAP-25 immunoreactive (IR) fibers (dark lines) in the bladder of two representative animals injected in the upper region of the bladder dome with
0.5 U of onabotulinumtoxinA (onabotA) or abobotulinumtoxinA (abobotA). From the left to the right are represented five sections taken from the dome to
the trigone. C,D: Photomontages of the pictures taken from the trigonal bladder sections (section V), which gave origin to the schematic representations in
image B. C.1,D.1: Expansion of the areas delimited by the rectangles in images C and D. cSNAp-25 immunostaining is observed as black lines.
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DISCUSSION
In clinical practice, onabotA and abobotA are frequently used
for the treatment of NDO andOAB despite the fact that only the
former has been through regulatory trials.1,2 Bioequivalence
between the two brands is impossible to establish at the
moment,mainly due to the fact that the potency determination
of onabotA uses a biochemical cell assay based on the
expression of cSNAP-25, whereas abobotA follows the classical
mice LD50 assay.11 Thus, the conversion ratio applied for
bladder use is empirically determined based on skeletal muscle
application, 1U of onabotA to 3–5U of abobotA.10,14,19
Our study allowed us to compare the number of cSNAP-25 IR
fibers present in themouse bladder under controlled conditions.
The number of positive cSNAP-25 fibers found/bladder section
after the administration of 0.5U of onabotA was 1.6 times
superior than that found for 0.5 units of abobotA. Thus, the ideal
conversion ratio should be substantially lower than that
currently reported in clinical practice. These results are in
agreementwith a recent study performed in a ratmodel of NDO
where a conversion ratio of onabotA and abobotA of 1:1.3Uwas
extrapolated, using cystometric parameters as outcome.20
Higher conversion ratios used in some OAB studies, like
1:2.5U, may explain why the proportion of urinary retentions
in patients treated with abobotA (42%) was much higher than
that observed in patients who received onabotA (23%).14
Another aspect to take into account is the spread capacity of
the two toxin formulations, which is dependent on two
phenomena. One is the movement of the fluid across the
bladder tissues, which is directly related to the volume of
injection.17 As the volumewas the same in all experiments, this
factor can be disregarded as a source of variation between the
experimental groups. The second phenomenon is the diffusion,
which follows a concentration gradient and may vary due to
differences in formulations. In our experiments, the higher
molecularweight of onabotA did not limit the spread across the
bladder wall once we found immunoreactivity against cSNAP-
25 in all bladder sections. The higher number of cSNAP-25 in the
lower bladder sections, which are the most distant from
the injection point, ought to be explained by the fact that the
trigone contains the highest density of nerve fibers.7,17
The present study showed that a single injection of the same
number of units of onabotA and abobotA in the same
concentration might induce the cleavage of SNAP-25 in a
remarkably different number of fibers. As a matter of fact, we
observed that the number of cSNAP-25 positive fibers could vary
three to five-fold, despite the fact that the needle used for
injection, the location of the injection and the operator were the
same in all experiments. Possible variations due to the
reconstitution process of the toxin were prevented by injecting
a whole set of animals using the same vial of each brand.
Translating this finding into clinical practice, it seems clear that
cSNAP-25 obtained after bladder wall injection of BoNT/A may
have profound variations that ought to be attributed to the
injection technique. The recommended administration method
for neurogenic and idiopathic detrusor overactivity requires 30
and 20 injections respectively,3 which may attenuate injection
variations. Nevertheless, a careful administration of botulinum
Fig. 2. Average number of cleaved synaptosomal-associated protein of
25 kDa (cSNAP-25) immunoreactive (IR) fibers in the bladder (60 sections
from the 12 animals of each experimental group) of animals injected with
0.5U of onabotulinumtoxinA (onabotA) and abobotulinumtoxinA (abobotA).
The differences have statistical significance (P< 0.01; t test). Error bars
show standard deviation.
Fig. 3. A: Total number of cleaved synaptosomal-associated protein of 25 kDa (cSNAP-25) immunoreactive (IR) fibers counted in the bladder of each animal
injected with 0.5U of onabotulinumtoxinA (onabotA; n¼ 12). B: Total number of cSNAP-25 IR fibers counted in the bladder of each animal injected with 0.5U
of abobotulinumtoxinA (abobotA; n¼ 12). On top of the horizontal lines are represented the average of cSNAP-25 IR fibers and the correspondent standard
deviations calculated for the four animals with the highest and lowest number of IR fibers. The differences have statistical significance (P< 0.001;
P< 0.01).
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toxin is a fundamental step to obtain consistently good
therapeutic results.21 This aspect was recently highlighted in a
subanalysis of phase 3 regulatory trials carried out in patients
with NDO. Patients without a positive response after the initial
onabotA injections had excellent responses in subsequent
treatments.8
One limitation of our study is that it was not carried out in
human tissue,which for obvious ethical reasons is impossible to
perform. Nevertheless, we chose mice because the bladder
innervation of this species is very similar to the human one. In
fact, both have the parasympathetic ganglia embedded in the
bladderwall, in contrastwith rat.22Another limitation is the fact
that mice have a bladder wall much thinner than that of
humans, which can increase the variability of the injections in
mice, and decrease it in humans. Additionally, it is impossible to
exclude the loss of toxin during the injection procedure and its
contribution to the variability of results. However, it is also
impossible to predict the occurrence of toxin backflow during
bladder injections in patients. Therefore, our results strongly
support the maintenance of injection protocols with a high
number of injection points, in order to decrease variability.
Another limitation can be ascribed to the method of counting
fibers in the bladder wall. However, fibers were counted by the
sameperson, in a blindway, indigitalized images. This approach
circumvented the potential error that could arise from counting
the nerve fibers directly through the microscope oculars.
CONCLUSIONS
In conclusion,we found that the relativepotencyofonabotA to
cleave SNAP-25 in mice is 1.6 times higher than that of abobotA,
indicating that higher conversion ratios may be excessive for
bladder application. Moreover, we found strong fluctuations in
the amount of cSNAP-25 that resulted from one injection of
onabotAor abobotA, suggesting that the spreadof the toxin from
the injection point is highly variable. When translating this
observation into clinical practice, a high number of bladder
injections may be preferable if this risk is to be overcome.
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Available online 25 May 2016Spinal cord injury (SCI) often leads to neurogenic detrusor overactivity (NDO) due to sprouting of sensory affer-
ents on the lumbosacral spinal cord. NDO is characterized by high frequency of voiding contractions and in-
creased intravesical pressure that may lead to urinary incontinence. The latter has been described as one of the
consequences of SCI that mostly decreases quality of life. Bladder wall injections of botulinum toxin A
(Onabot/A) are an effective option to manage NDO. The toxin strongly impairs parasympathetic and sensory
ﬁbres coursing the bladder wall. However the robust parasympathetic inhibition may inhibit voiding contrac-
tions and cause urinary retention in patients that retain voluntary voiding. Here, we hypothesised that by
restricting the toxin activity to sensory ﬁbres we can improve NDO without impairing voiding contractions.
In the present work, we assessed the effect of Onabot/A on sensory neurons in chronic (4 weeks) SCI rats by
injecting the toxin intrathecally (IT), at lumbosacral spinal cord level. This route of administration was shown
before to have an effect on bladder pain and contractility in an animal model of bladder inﬂammation. We
found that IT Onabot/A led to a signiﬁcant reduction in the frequency of expulsive contractions and a normaliza-
tion of bladder basal pressure whilemaintaining voiding contractions of normal amplitude. Cleavage of SNAP-25
protein occurred mainly at the dorsal horn regions where most of the bladder afferents end. Cleaved SNAP-25
was not detected inmotor or preganglionic parasympathetic neurons. A signiﬁcant decrease in CGRP expression,
a peptide exclusively present in sensory ﬁbres in the spinal cord, occurred at the L5/L6 segments and associated
dorsal root ganglia (DRG) after Onabot/A injection in SCI animals. Onabot/A strongly increased the expression of
ATF3, a marker of neuronal stress, in L5/L6 DRG neurons.
Taken together, our results suggest that IT Onabot/A has a predominant effect on bladder sensory ﬁbres, and that
such effect is enough to control NDO following chronic SCI. The mechanism of action of Onabot/A includes not
only the cleavage of SNAP-25 in sensory terminals but also impairment of basic cellular machinery in the cell
body of sensory neurons.
© 2016 Elsevier Inc. All rights reserved.Keywords:
Spinal cord injury
Urinary bladder
Botulinum toxin
Neurogenic detrusor overactivity1. Introduction
The incidence andprevalence of spinal cord injury (SCI) are difﬁcult to
estimate on a yearly basis but it is assumed that N2 million people; CGRP, calcitonin gene-related
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67worldwide live with SCI (Lee et al., 2014). Despite recent advances, SCI
is still a highly debilitating condition. Depending on the magnitude of
SCI, affected individuals may present complete or incomplete loss of
sensory andmotor functions.With adequate treatment, certain neurolog-
ical problems may be overcome, at least partially, during the ﬁrst year
after SCI, and patients with incomplete cord sectioning recover some
limb function (French et al., 2010). A critical aspect for SCI patients is
loss of voluntary control over bladder function. As amatter of fact, urinary
incontinence, due to development of neurogenic detrusor overactivity
(NDO), is reported by most SCI patients and represents the major cause
for a decreased quality of life (Simpson et al., 2012). Indeed, after improv-
ing motor and sensory function, regaining bladder control is the highest
160 A. Coelho et al. / Experimental Neurology 285 (2016) 159–166priority for SCI patients (Collinger et al., 2013; French et al., 2010;
Simpson et al., 2012), due to its heavy impact on social engagement and
performance of daily tasks.
Experimental studies have shown that bladder C-ﬁbres play a
fundamental role in the appearance of NDO. De Groat and co-
workers demonstrated that after chronic SCI in cats, NDO emergence
could be abolished by the administration of systemic capsaicin
(Cheng et al., 1995, 1999). These data suggested that after SCI, the
synaptic reorganization responsible for the new abnormal spinal
micturition reﬂex is mediated by C-ﬁbres (de Groat et al., 1990). In
chronic SCI rats, the sprouting of peptidergic ﬁbres around the
preganglionic parasympathetic neurons of the lumbosacral spinal
cord conﬁrmed the role of C-ﬁbres in the previous physiological
observations (Zhang et al., 2008). Accordingly, the impairment of
C-ﬁbres has been attempted for long time to control NDO.
Intravesical administration of capsaicin and resiniferatoxin (RTX)
has been assessed in pilot clinical trials with considerable success
but unfortunately, were not followed by appropriate regulatory
trials (Cruz et al., 1997; Fowler et al., 1994).
Current management of NDO include bladder injections of
OnabotulinumtoxinA (Onabot/A) (Cruz et al., 2011; Kennelly et al.,
2015; Schurch et al., 2000). Successful results rely on the toxin's
ability to block neuroexocytosis, by cleaving the SNAP-25 protein
required for the accurate assembly of synaptic vesicles with the pre-
synaptic cell membrane (Chancellor et al., 2008). Thus, the detection
of cleaved SNAP-25 (cSNAP-25) has been used as a reliable marker of
Onabot/A activity both in peripheral and central nervous systems
(Coelho et al., 2012a, 2012b, 2014; Oliveira et al., 2015). Onabot/A
is a non-speciﬁc neurotoxin that impairs almost all motor but only
half of sensory ﬁbres coursing the bladder wall (Coelho et al., 2010,
2012a, 2012b). This dual effect may certainly contribute to the high
cure rates of urinary incontinence and strong reduction in the maxi-
mal detrusor pressure obtained with this toxin in patients with NDO
of spinal origin. However, in patients who void spontaneously the
predominant action on parasympathetic ﬁbres is also responsible
for a high rate of urinary retention, forcing patients to initiate inter-
mittent self-catheterization. (Cruz et al., 2011; Cruz and Nitti, 2014;
Ginsberg et al., 2013).
It is accepted that an important step ahead in botulinum toxin ﬁeld
would be the development of a toxin that speciﬁcally targets sensory
ﬁbres. In this way one expects to control NDO while minimizing the
risk of urinary retention as observed in the pilot studies with capsaicin
or RTX. However, since modiﬁed toxins are not yet available, testing
such hypothesis for botulinum toxin A requires amethod of administra-
tion that only targets sensory ﬁbres. In a recent study, we demonstrated
a reduction in abdominal pain and bladder hyperactivity in a model of
chronic bladder inﬂammation after intrathecal (IT) administration of
botulinum toxin at L5/L6 spinal cord level (Coelho et al., 2014a,
2014b). Cleaved SNAP-25 was concentrated between L4 and L6 spinal
cord segments and none could be seen on motor neurons or in pregan-
glionic parasympathetic neurons of the intermediolateral gray matter.
Accordingly, no locomotion deﬁcits were observed in the injected
animals and the ability of the bladder to contract and empty completely
at voiding remained intact. Thus, in the present study we evaluated the
predominant sensory effect of intrathecal administration of botulinum
toxin on the bladder function of chronic SCI rats and investigate putative
underlying mechanisms of action.
2. Methods
2.1. Animals
All experiments were performed in female Wistar rats (Charles
River, France) weighing 220–250 g that were maintained under a 12 h
light/12h dark schedule, with free access to food andwater. Experimen-
tal procedureswere carried out according to the EuropeanCommunities68Council Directive 2010/63/EU. All efforts were done to reduce the num-
ber of animals used and their suffering.
2.2. Reagents and drugs
Surgeries were performed under deep anaesthesia induced by an
intraperitoneal (i.p.) injection of a mixture of ketamine (6 mg/100 g
of body weight) andmedetomidine (0.025mg/100 g of body weight)
diluted in saline. For cystometries and terminal handling animals re-
ceived a subcutaneous (s.c.) injection of urethane (1.2 g/kg of body
weight). OnabotulinumtoxinA (Onabot/A) was purchased from
Allergan, CA, USA. The rabbit polyclonal cSNAP-25 antibody raised
against the truncated C-terminal peptide of SNAP-25, was a kind
gift from Ornella Rossetto and has been previously described
(Antonucci et al., 2008; Coelho et al., 2014a, 2014b). Mouse mono-
clonal calcitonin gene-related peptide [(CGRP) (ab81887)], rabbit
polyclonal β-actin (ab8227) and mouse monoclonal glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (ab8245) antibodies
were obtained from Abcam, Cambridge, UK. Rabbit polyclonal
activating transcription factor 3 (ATF3) (SC-188) and HRP-labelled
secondary antibodies were purchased from Santa Cruz Biotechnolo-
gy, Germany. Alexa™ 568 and 488 ﬂuorochrome-labelled secondary
antibodies, produced in donkey, were obtained from Molecular
Probes Europe, Life Technologies, UK.
2.3. Spinal cord transection and catheter implantation
Themodel of chronic SCI induced by a complete spinal cord transec-
tion at the level of low thoracic spinal segments T8/T9 was chosen for
the present study (Cruz et al., 2006; de Groat et al., 1990; Frias et al.,
2015). Animals were divided into four experimental groups: (A) spinal
intact + saline IT (n= 8); (B) spinal intact + Onabot/A IT (n= 8); (C)
SCI+ saline IT (n= 10); (D) SCI+Onabot/A IT (n= 10). Groups A and
B were used as sham-operated controls, in which the spinal cord was
exposed but not sectioned. Groups C and D were submitted to SCI. All
animals underwent surgical implantation of a sterile silicone catheter
(SF Medical; internal diameter: 0.3 mm, outer diameter: 0.635 mm)
(Coelho et al., 2014a, 2014b). Brieﬂy, under deep anaesthesia animals
were submitted to laminectomy at T8/T9 level. The meninges were
pierced and a silicone catheter was inserted in the subarachnoid space
and pushed until the tip reached the L5/L6 spinal cord segment. The
other tip was sealed and placed subcutaneously at the back of the
neck for drug delivery 4 weeks after surgery (saline for groups A and
C or Onabot/A for groups B and D). Catheter placement was followed
by complete sectioning of the spinal cord in groups C and D and
haemostatic sponge was placed between the retreated ends of the
cord. Animals were left to recover and carefully monitored, receiving a
daily i.p. injection of antibiotic (ciproﬂoxacin, 1 mg/kg) for 10 days
after surgery. Bladders were manually emptied by abdominal compres-
sion to avoid urinary retention, twice daily for a period of 2 weeks.
Female rats were preferred due of the difﬁculty to manage urinary re-
tention in male rats.
2.4. IT drug delivery and cystometries
Four weeks after surgery, the catheter tip at the animal back was
externalized and saline or Onabot/A (5 U diluted in 50 μL of saline)
were delivered. Three days later, animals underwent cystometry. Ani-
mals were anaesthetized (urethane 1.2 g/kg, subcutaneous injection)
and body temperature was maintained at 37 °C with a heating pad.
Bladders were exposed via a midline low abdominal laparotomy. A
21-gauge needle connected to an infusion pump and to a pressure
transducer was inserted into the bladder dome. Animals were left un-
touched for 15–30min to allow bladder stabilization, after which saline
infusion was initiated (constant rate of 6 mL/h), while intraluminal
pressure was measure and recorded for 1 h. The urethra remained
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easily be expelled during bladder contractions. Cystometrograms were
analysed and frequency, amplitude and peak and basal pressure of blad-
der reﬂex contractions were quantiﬁed using the LabScribe software
(iWorx, World Precision Instruments).
2.5. Tissue processing for immunohistochemistry
After cystometries, experimental groups were divided. Half of the
animals from each group were perfused through the ascending aorta
with calcium-free Tyrode's solution (0.12 M NaCl, 5.4 mM KCl, 1.6 mM
MgCl2·H2O, 0.4 mM MgSO4·H2O, 1.2 mM NaH2PO4·H2O, 5.5 mM glu-
cose and 26.2 mM NaHCO3) followed by cold 4% paraformaldehyde
(PFA) in 0.1 M phosphate buffer (PB). Before tissue collection, the posi-
tion of the IT catheter was veriﬁed and only the animals in which the
catheter was correctly placed were considered for further analysis.
The spinal cord segments L5 and L6 and respective dorsal root ganglia
(DRG) were collected, post-ﬁxed for 4 h in 4% PFA and cryoprotected
overnight in 30% sucrose in PBwith 0.1% sodiumazide. Transverse serial
sections (20 μm for spinal cord segments and 10 μm for DRG) were ob-
tained in a Leica cryostat, collected in Superfrost Plus slides and stored at
−20 °C until further processing.
For immunoﬂuorescence analysis, alternate slides were thawed,
washed with saline 0.1 M phosphate buffer (PBS) and PBS contain-
ing 0.3% Triton X-100 (PBST) and blocked with 10% of normal horse
serum (NHS) in PBST for 1 h. Primary antibodies (anti-cSNAP-25
1:1000; anti-CGRP 1:8000; anti-ATF3 1:200) were diluted in 2%
NHS in PBST for 48 h at 4 °C. After several washes with PBST,
sections were incubated with species-speciﬁc Alexa™ ﬂuoro-
chrome-labelled secondary antibodies for 1 h at room temperature.
After several washes with PBST and PBS, sections were mounted
with an anti-fade mounting medium (Thermo Fischer Scientiﬁc,
MA, USA) and representative images were obtained using a Zeiss
microscope (Axioimager Z1, Zeiss Z1 from Zeiss, Oberkochen, Ger-
many) using the Axiovision 4.8 software. The intensity of CGRP
immunoreactivity in the spinal cord was quantiﬁed by densitome-
try using the Fiji software (Schindelin et al., 2012). Staining inten-
sity was averaged from 15 to 20 spinal sections per animal by
selecting the dorsal horn area exhibiting CGRP immunoreaction
(laminae I, II, III and IV), and after deduction of background inten-
sity. In DRG, the number of nuclei positively labelled for ATF3 was
averaged after counted using the Fiji software. In both cases, data
are presented as mean ± SEM and p b 0.05 was considered statisti-
cally signiﬁcant.
2.6. Tissue processing for western blotting
After cystometries half of the animals from each experimental group
were euthanized and L5/L6 DRGwere collected and immediately stored
at −80 °C until further processing. Tissue was homogenized using a
lysis buffer (Tris 50 nM, NaCl 150 nM, Triton X-100 0.5%, EDTA 1 nM,
pH 7.6) supplemented with protease inhibitor cocktail (Roche, Basel,
Switzerland). Homogenates were sonicated and the protein concentra-
tion determined using the Bradford assay (Biorad, California, USA). Thir-
ty μg of tissuehomogenateswere separated on a 12% polyacrylamide gel
using and transferred onto a nitrocellulose membrane. Membranes
were blocked in 5% milk in Tris buffer saline with 0.1% Tween-20
(TBST) and incubated with anti-CGRP 1:8000 in 5% bovine serum
albumin (BSA) in TBST overnight at 4 °C. Blots were then incubated
with anti-mouse HRP-conjugated antibody (1:5000) and β-actin
(1:5000) or GAPDH (1:10,000) for 1 h at room temperature. The
bound antibodies were detected by chemiluminescence (Supersignal
West Pico Chemiluminescence Substrate, Pierce). Digital images were
obtained using a Chemidoc MP System Imager and the ImageLab 5.1
software (Biorad). Membranes were then stripped by incubatingmem-
branes with 10% SDS for 30 min at room temperature. Following a69second blockade, membranes were re-incubated with anti-ATF3 1:200
overnight at 4 °C. Signal detection was performed as previously
described. Digital images of western-blots were obtained and protein
levels of CGRP and ATF3 were quantiﬁed by densitometry and normal-
ized against beta-actin or GAPDH using the Fiji software (Schindelin et
al., 2012).
2.7. Data analysis
All data was statistically analysed using the one-way ANOVA follow-
ed by the Tukey's multiple comparison test using the GraphPad Prism 6
software. Data are presented as mean ± SEM and p b 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Intrathecal administration of Onabot/A improves bladder function after
spinal cord transection
Spinal intact animals that received IT saline exhibited normal
bladder reﬂex activity, characterized by regular contractile activity
during cystometry with an urinary frequency of 0.5 ± 0.1 contrac-
tions/min, an amplitude of voiding contractions of 31.9 ± 4.3 cm
H2O and a basal pressure of 8.6 ± 3.1 cm H2O (Fig. 1A). The adminis-
tration of Onabot/A IT did not cause any alteration in bladder
contractions. Hence, no changes of cystometric parameters were ob-
served (Fig. 1B). In these animals, frequency and amplitude of
voiding contractions were 0.5 ± 0.1 contractions/min and 32.6 ±
2.9 cm H2O, respectively, and basal pressure was 4.5 ± 2.0 cm H2O
(Fig. 1, graphs A to C).
In SCI animals, the typical abnormal pattern of bladder reﬂex activi-
ty, urodynamically designated as NDO, was evident 4 weeks after
surgery (Fig. 1C). At this time, the frequency of bladder contractions
was signiﬁcantly increased to 2.0 ± 0.8 contractions/min (p b 0.001
versus spinal intact). The amplitude of these reﬂex contractions was
signiﬁcantly decreased to 14.9 ± 9.5 cm H2O (p b 0.05 versus spinal
intact), while basal pressure signiﬁcantly increased to 31.7 ± 13.1 cm
H2O (p b 0.01 versus spinal intact) (Fig. 1, graphs A to C). Administration
of saline IT did not induce any alteration of bladder activity in SCI rats.
In contrast with saline, IT administration of Onabot/A 4 weeks after
SCImarkedly changed bladder function (Fig. 1D). The toxin signiﬁcantly
decreased the frequency of expulsive bladder contractions (0.9 ±
0.3 contractions/min). In addition, voiding contractions maintained
normal amplitude and could empty the bladder. Bladder baseline pres-
sure was normalized (31.2 ± 12.0 cm H2O and 14.3 ± 7.8 cm H2O,
respectively, Fig. 1, graphs).
As in previous studies (Coelho et al., 2014a, 2014b), urinary
retention, other visceral side effects, motor impairment, worsening
of limb paralysis (in SCI animals) or respiratory depression were
never observed in any of the spinal intact and SCI animals receiving
IT Onabot/A.
3.2. Intrathecal administration of Onabot/A cleaves SNAP-25 on
lumbosacral spinal cord neurons
At the L5 and L6 spinal cord segments, where themajority of central
projections frompeptidergic sensory neurons that innervate the urinary
bladder are located (Honda, 1985; Morgan et al., 1981; Nadelhaft and
Booth, 1984), strong cSNAP-25 immunoreactivity was found in animals
treated with IT Onabot/A (Fig. 2). The immunoreactive ﬁbres were
mainly observed coursing laminae I and II of the dorsal horns (Fig. 2A)
and also detected in the proximity of motor neurons' cell bodies in the
ventral horns (Fig. 2C). The cleaved form of SNAP-25 was also found,
but to a much lower intensity, in spinal cord segments at the vicinity
of the administration area, such as L4 and S1. Motor or parasympathetic
Fig. 1. Cystometrograms depicting the voiding pattern of all experimental groups. In spinal intact animals, irrespective of IT administration of saline or Onabot/A, a normal voiding pattern
is observed (A and B, respectively). In SCI animals that received saline, a typical pattern of NDO is well established (C). SCI animals treated with Onabot/A showed an improved voiding
pattern with signiﬁcantly reduced urinary frequency and basal pressure and increased amplitude of voiding contractions (D). Analysis of urodynamic parameters such as frequency of
voiding contractions (E), amplitude of voiding contractions (F) and basal pressure (G) are detailed in the graphs. Graphs represent the average ± SEM. *p ≤ 0.05, **p ≤ 0.01 and
***p ≤ 0.001; one-way ANOVA followed by Newman-Keuls multiple comparison test.
162 A. Coelho et al. / Experimental Neurology 285 (2016) 159–166preganglionic nerves in the intermediolateral nucleus (IML) did not
express cleaved SNAP-25 (Fig. 2B).
3.3. Intrathecal administration of Onabot/A alters the expression of CGRP at
the spinal cord after spinal cord injury
In spinal intact animals the classic bilateral dorsal horn distribu-
tion of CGRP-positive processes was observed in the L5 and L6 seg-
ments of the spinal cord. CGRP immunoreactivity was primarily
detected in nerve endings coursing in the superﬁcial laminae (I and
II) and less abundantly in lamina X (Fig. 3A). Intrathecal administra-
tion of Onabot/A in spinal intact animals did not change the intensity
of CGRP immunoreaction (Fig. 3B). In spinal sections from SCI
animals, CGRP immunoreaction was more intense and the CGRP-
positive processes were longer with immunoreactive terminals
penetrating laminae III and IV and abundantly detected in lamina X
and Lissauer's tract (Fig. 3C; p b 0.005 versus spinal intact). Intrathe-
cal administration of Onabot/A 4 weeks after SCI reduced the
intensity of CGRP immunoreactivity to values comparable to those
observed in spinal intact animals (Fig. 3D).703.4. Intrathecal administration of Onabot/A causes neuronal changes at the
dorsal root ganglia
In spinal intact animals, CGRP was present in the cytoplasm of small
diameter neurons of the L5 and L6 DRG. Intrathecal administration of
Onabot/A to these animals appeared to decrease the number of DRG
neurons expressing CGRP (Fig. 4). To quantify this qualitative change
western blot was performed to assess changes of CGRP levels in the
DRG. In SCI animals, CGRP expression increased 302% (p b 0.005) in
comparison with spinal intact rats. Intrathecal injection of Onabot/A
delivered to SCI animals, signiﬁcantly reduced CGRP expression to con-
trol levels (Fig. 4).
We also analysed the expression of ATF3, a nuclearmarker of neuro-
nal stress (Chen et al., 1996; Tsujino et al., 2000). Immunostaining of
DRG sections identiﬁed ATF3 presence in neuronal nuclei of all experi-
mental groups (Fig. 5). A qualitative inspection of those DRG sections
suggested a substantial increase of ATF3 in SCI animals treated with IT
Onabot/A (Fig. 5A and B). Quantiﬁcation of ATF3 positively-labelled
nuclei in L5 and L6 DRG sections showed that in spinal intact animals
the number of nuclei was 0.5 ± 0.1 and IT administration of Onabot/A
Fig. 2. Immunohistochemistry for cleaved SNAP-25 in the lumbosacral spinal cord.
Cleaved SNAP-25 was detected by ﬂuorescence immunohistochemistry in the L5 and L6
spinal segments after IT administration of Onabot/A. The cleaved protein was observed
in the dorsal horn mainly in the superﬁcial laminae I and II (A) and in nerve ﬁbres
around the motor neurons of the ventral horn (C). No immunoreaction was found in
motor neurons of the intermediolateral gray matter (IML) (B).
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induced a signiﬁcant increase of ATF3 positive nuclei (2.976 ± 0.453)
and IT administration of Onabot/A in SCI animals further increased the
expression of that transcription factor (5.084 ± 1.864) (Fig. 5D). Quan-
titative analysis of the total protein expression showed similar results
(Fig. 5C and E). ATF3 was present at very low levels in DRG from spinal
intact animals (Fig. 5C and E). ATF3 expression slightly increased in SCI
rats treated with IT saline (178.3% compared to spinal intact) and
further raised signiﬁcantly (296.1% compared to spinal intact,
p b 0.05) in SCI rats treated with IT Onabot/A (Fig. 5C and E).714. Discussion
The main ﬁnding of the present study is that IT administration of
Onabot/A causes a profound impairment of sensory ﬁbres through a
mechanism that includes SNAP-25 cleavage in terminals at the spinal
cord dorsal horn as well as changes in gene transcription at the DRG
neurons in chronic SCI rats. As a consequence of these changes in senso-
ry neurons at the lumbosacral spinal cord level, a marked improvement
in neurogenic bladder dysfunction was observed.
We found that IT administration of Onabot/A al lumbosacral spinal
cord level improves SCI-induced NDO, as the abnormal pattern of
micturition observed in rats 4 weeks after complete SCI was signiﬁcant-
ly improved by this treatment. Indeed, 48 h after toxin delivery, the fre-
quency and baseline pressure of reﬂex bladder contractions were
signiﬁcantly decreased. Despite being IT injected, Onabot/A did not
cause any case of urinary retention, excluding any remarkable impair-
ment of the parasympathetic innervation of the bladder. Moreover, IT
treated SCI rats did not show any obvious weakening of the upper
limb movements when compared to saline treated SCI animals. Also,
no deaths by respiratory failure occurred in the treated group
conﬁrming the absence of any relevant paralysis of the respiratorymus-
cles. This is in agreement with our previous observations in naïve and
bladder inﬂamed animals injected IT with Onabot/A at the same spinal
cord level to treat bladder pain. Toxin treated rats maintained bladder
contractility and did not develop urinary retention. Moreover, locomo-
tion was not affected since walking distance in the open ﬁeld test was
similar to saline injected and sham operated rats. Reduction of pain
levels was striking in animals with bladder inﬂammation that received
IT Onabot/A (Coelho et al., 2014a, 2014b). Altogether these ﬁndings
rule out a major impairment of the parasympathetic activity as the
main reason for bladder improvement in SCI rats treated with IT
Onabot/A.
The effect of IT Onabot/A in lumbosacral sensory endings was dem-
onstrated in the present study. We observed intense immunoreactivity
for cSNAP-25 in Onabot/A-treated rats restricted to the superﬁcial
dorsal horn of lumbosacral segments, where most sensory ﬁbres termi-
nate. In contrast, no cSNAP-25was found in cell bodies of neurons locat-
ed in the ventral horn or IML which might correspond to motor or
preganglionic parasympathetic neurons.
The typical increase of CGRP immunoreactivity in the lumbosa-
cral spinal cord in chronic SCI rats (Zinck et al., 2007) was also
observed in the present study and substantially reduced by IT
Onabot/A. One should recall here that a similar decrease in CGRP im-
munoreactivity was reported in our previous work on IT Onabot/A in
a model of chronic bladder inﬂammation (Coelho et al., 2014a,
2014b). This change in CGRP expression, a peptide exclusively
present in sensory terminals in the spinal cord, is an additional
evidence of the strong effect of IT Onabot/A on sensory ﬁbres. Addi-
tionally, we demonstrated that IT injected Onabot/A caused pro-
found changes in lumbosacral DRG neurons. This was evidenced in
two different ways: CGRP expression was decreased in the cell
bodies of DRG neurons while there was a strong up-regulation of
ATF3. The latter is an immediate-early transcription factor that en-
codes the transcription of genes related to the instant response to
injury, survival and regeneration (Hai et al., 1999; Tsujino et al.,
2000). Previous works supporting this mechanism have shown
ATF3 up-regulation in the nuclei of sensory neurons following stress
and traumatic injury in animal models of spinal cord compression
injury, spinal hemisection and monoarthritis (Hai et al., 1999;
Nascimento et al., 2011; Tsujino et al., 2000). Also, it has been
shown that ATF3 is up-regulated in the human DRG after traumatic
dorsal root avulsion (Linda et al., 2011). In our work, sham-operated
animals expressed residual levels of ATF3, possibly reﬂecting the
effects of surgical procedures as it has been previously observed
(Huang et al., 2006). Spinal cord injured rats had a marginal increase
in the number of ATF3-positive neurons, as a consequence of the
Fig. 3. Distribution of CGRP in the lumbosacral spinal cord. CGRP was detected by immunohistochemistry in the dorsal horn of the L5 and L6 spinal segments. In spinal intact animals,
irrespective of the treatment with saline or Onabot/A CGRP was distributed mainly in the superﬁcial laminae (I and II) (A and B). Four weeks after SCI, CGRP distribution increased and
was observed in deeper laminae (III and IV) as well as laminae X and Lissauer's tract (C). When Onabot/A treatment was delivered to SCI animals, the distribution of CGRP was similar
to the controls (D). The intensity of CGRP immunoreactivity was quantiﬁed by densitometry and average values are detailed in the graph (E). Graph columns represent average
intensity per experimental group ± SEM. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001; one-way ANOVA followed by Newman-Keuls multiple comparison test.
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with previous works where ATF3 was signiﬁcantly increased in the
DRG after spinal cord compression injury (Huang et al., 2006). Sur-
prisingly, IT Onabot/A markedly increased ATF3 in DRG cells further
suggesting the sensory impairment caused by the IT toxin
administration.
The increase of ATF3 shown in this work raises the possibility of
another mechanism of action for Onabot/A in what concerns sensoryFig. 4. Expression of CGRP in the dorsal root ganglia. CGRP expression in L5 and L6 dorsal root ga
(A) and (B) show CGRP immunoreaction in the L6 DRG of SCI animals treatedwith saline and O
β-actin (42 kDa) corresponding to each experimental group (from left to right there are lanes fr
A). (D) represents the averages of CGRP relative expression determined for each group, quanti
Onabot/A did not alter the levels of CGRP expression (C, D). Four weeks after SCI, express
expression decreased markedly to levels identical to those found in spinal intact animals (B, C
multiple comparison test.
72ﬁbres. Under the classical mechanism of action of Onabot/A on SNAP-
25, we would predict that CGRP release was impaired and that this
peptide would accumulate in sensory neurons. Instead, we observed a
decrease of CGRP in the sensory terminals, located in the dorsal horn,
and in the cell body of DRG neurons. This neuropeptide is synthesized
in the soma and transported to the terminal processes coursing in lam-
inae I–II of the spinal cord. Thus, this study suggests that Onabot/A
affects sensory ﬁbres not only at their terminals but also at their cellnglia was detected by immunohistochemistry and quantiﬁed bywestern immunoblotting.
nabot/A, respectively. (C) represents western immunoblot detection of CGRP (25 kDa) and
om spinal intact+ saline, spinal intact+Onabot/A, SCI 4w+ saline and SCI 4w+Onabot/
ﬁed by western immunoblotting and normalized against β-actin. In spinal intact animals,
ion of CGRP in DRG increased signiﬁcantly (A, C, D). After Onabot/A treatment CGRP
, D). *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001; one-way ANOVA followed by Newman-Keuls
Fig. 5. Expression of ATF3 in the dorsal root ganglia. ATF3 expression in L5 and L6DRGwas detected by immunohistochemistry and quantiﬁed bywestern immunoblotting. In spinal intact
animals ATF3 is expressed in low levels irrespective of the treatmentwith saline orOnabot/A. SCI lead to a signiﬁcant increase of ATF3 expression levels andnumber of labellednuclei (C, D,
E) which further raised after Onabot/A treatment (C, D, E). (A) and (B) represent ATF3 immunoreaction at the L6 DRG of SCI animals treated with saline and Onabot/A, respectively. (C)
represents western immunoblot detection of ATF3 (30 kDa) and GAPDH (37 kDa) corresponding to each experimental group (from left to right there are represented lanes from spinal
intact+ saline, spinal intact+ Onabot/A, SCI 4w+ saline and SCI 4w+Onabot/A). (D) represents the average of ATF3 positive nuclei in the L5 and L6 DRG. (E) represents the average of
ATF3 relative expression determined for each group, quantiﬁed by western immunoblotting and normalized against GAPDH. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001; one-way ANOVA
followed by Newman-Keuls multiple comparison test.
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protein synthesis, post-translational modiﬁcations, packing and/or
axonal transport. Thus, it seems that the effects of Onabot/A on neuro-
transmission are not restricted to cleavage of synaptic proteins but
may result from profound alteration of the basic neuronal metabolism.
This hypothesis has been raised by other studies that showed a toxin
activity in cellular mechanisms independent of SNAP-25 cleavage such
as the arachidonic acid pathway, neuritogenesis, cell cycle, apoptosis
and gene expression (Matak and Lackovic, 2015).
Despite the effective control of NDO with IT Onabot/A, the leading
objective of this study was not to demonstrate an eventual clinical
role of this route of administration for the toxin inNDOpatients. Bladder
wall injections of Onabot/A are highly effective to manage NDO symp-
toms in SCI patients, given the marked long-lasting improvement of
urinary incontinence and decrease of maximal detrusor pressure seen
in the clinical pivotal trials (Cruz et al., 2011; Ginsberg et al., 2012).
Rather, the objective was to investigate the possibility of controlling
NDO of spinal cord origin by the predominant impairment of bladder
sensory ﬁbres with botulinum toxin while sparing the parasympathetic
motor innervation of the bladder. One should take in mind that when
injected in the bladderwall, Onabot/A acts preferentially on parasympa-
thetic ﬁbres, as indicated by the presence of cSNAP-25 immunoreactiv-
ity in 85% of cholinergic ﬁbres after toxin injection in the rat bladder73(Coelho et al., 2010, 2012a, 2012b). These cholinergic ﬁbres also belong
to pre-ganglionic parasympathetic neurons (Coelho et al., 2012a,
2012b) which may indicate that synaptic transmission in parasympa-
thetic ganglia embedded in the bladder wall is also impaired by bladder
wall injections of botulinum toxin A. On the contrary, the effect of blad-
der wall injections on sensory ﬁbres is very modest, only one third of
sensory ﬁbres coursing the bladder wall exhibited strong cSNAP-25
immunoreactivity (Coelho et al., 2012b). According to the ﬁndings of
this study, we can expect that a future recombinant botulinum toxin
with a strong speciﬁcity for sensory ﬁbres might be used to effectively
treat NDO without the risk of impairing parasympathetic-mediated
bladder voiding contractions.5. Conclusion
Our study highlights that Onabot/A has a strong sensory effect.
Restriction of the toxin activity to sensory terminals after intrathecal
delivery is enough to control bladder function in SCI animals. The effect
of Onabot/A on sensory ﬁbres is not restricted to the cleavage of SNAP-
25 and includes the impairment of basic cytoplasmic machinery
required to the synthesis of neuropeptides, protein synthesis and/or
axonal trafﬁcking.
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Abstract 
Neurogenic detrusor overactivity (NDO) affects the great majority of spinal cord injury 
(SCI) patients, being in the top list of their concerns, and require rapid, safe and effective 
management strategies. Bladder-wall injections of OnabotulinumtoxinA (Onabot/A) emerged as 
a promising treatment, resulting in significant urodynamic benefits and clear improvement in 
patients’ quality of life. Toxin-based therapy is currently initiated in patients that do not respond 
to antimuscarinics and in a chronic phase of the lesion, when NDO is established. Here we 
evaluated the possibility to attenuate NDO development if we provide treatment to SCI rats in 
an early phase of disease progression, during spinal shock. Our results suggest that an early 
intervention with Onabot/A is not effective in preventing NDO development, with SCI rats 
treated with the toxin presenting the urodynamic pattern of NDO 4 weeks after lesion. The 
analysis of bladder, L5-S1 dorsal root ganglia (DRG) and spinal cord (SC) tissue corroborate 
findings on bladder reflex activity, with no significant changes emerging from Onabot/A early 
administration. In addition, here we raised the hypothesis that the absence of toxin-mediated 
alterations in urodynamics and neuronal reflex inducing NDO might reflect the toxin incapacity 
to exert its effect on synaptosomal nerve-associated protein 25 (SNAP-25) during the period of 
spinal shock. 
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Introduction 
Botulinum toxin A (BoNT/A) is the current gold-standard NDO treatment for patients 
that are refractory to antimuscarinic therapy [1-4]. Several studies show that intra-detrusor 
injections of BoNT/A result in a marked reduction in the frequency of episodes of urinary 
incontinence as well as improvement of several urodynamic parameters, including intravesical 
pressure [5, 6]. When internalized by active pre-synaptic neuronal terminals, via the synaptic 
vesicle glycoprotein 2 (SV2) [7], this neurotoxin specifically cleaves the synaptossome associated 
protein of 25 kDa (SNAP-25), a protein essential for neurotransmitter release, and effectively 
blocks neurotransmission. Because virtually all bladder fibres express SV2 and SNAP25 [8], 
intradetrusor administration of BoNT/A is able to block parasympathetic, sensory and 
sympathetic bladder fibres [8, 9]. The effects of bladder injection with this neurotoxin are long-
lasting with little secondary effects, resulting in improved quality of life for NDO patients  [5]. 
Management of NDO is typically initiated when urinary incontinence is already a stable 
fixed condition, with little chances of disappearing, and when kidney damage secondary to 
detrusor-sphincter-dyssynergia (DSD) may have already occurred. However, an increasing 
number of studies suggest that assessment of urinary dysfunction, as NDO arising after SCI, 
should be an early priority and therapeutic intervention should also be initiated at early time 
points of disease progression [10]. This is supported by studies demonstrating positive effects 
on bladder function of SCI patients and experimental animals were found when treatments were 
initiated during spinal shock. These treatments included neuromodulation and antimuscarinics 
[11-13]. In the present study we investigated if, like other treatments, early administration of 
BoNT/A would results in improved bladder function in SCI rodents. 
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Materials and Methods 
Spinal cord injury rat model 
Experiments were performed in in-house bred, 220 to 290 g female Wistar rats (Charles 
River, France), maintained under a 12-hour light/ dark schedule, with ad libitum access to food 
and water. We used the rat model of largely incomplete spinal cord transection (SCT) at the high 
thoracic levels of T8/T9. After anaesthesia and dorsal shaving, the T13 vertebra was identified 
by palpation and the T7 to T10 vertebra exposed. Following a laminectomy, the spinal segments 
T8/T9 were visualized and a scalpel was inserted approximately 5mm perpendicularly until the 
tip touched the bone. All surgeries were performed by the same experimenter to ensure 
reproducibility. The scalpel was removed and a small piece of sterile gelfoam was inserted to 
limit bleeding. Sham-operated rats were used as controls. Animals were left to recover, receiving 
daily ciprofloxacin (1mg/kg) for 10 days after surgery. Bladders were manually emptied daily, by 
abdominal compression for a period of 2 to 3 weeks. 
Experimental groups and treatments 
Three groups of animals (n=4/groups) were used to evaluate changes in in bladder 
expression of SNAP-25, GAP43, TRPV1 and VAChT associated with the progression of bladder 
dysfunction. Bladder tissue was collected from spinal intact (INT) and from SCT rats 1 and 4 
weeks after spinal lesion (1 wk and 4 wks, respectively). 
Three days after spinal injury, 10U of the BoNT/A formulation OnabotulinumtoxinA 
(Onabot/A; Allergan, CA), diluted in 100 uL of saline, was injected in 10 points of the bladder 
wall of SCT (n=6) or sham-operated rats (n=3). Control SCT (n=6) and sham animals (n=5) 
received only saline. Toxin dosage was selected based on previous studies demonstrating its 
effectiveness in chronic NDO rats [14]. 
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Recordings of bladder reflex activity 
Animals underwent cystometries 4 weeks after Onabot/A injection, a time-point after 
spinal injury when NDO is typically present. After deep anaesthesia induced by subcutaneous 
urethane (1.2 g/Kg), cystometries were performed for 1 hour with constant body temperature 
of 37°C, maintained with a heating pad. Briefly, following abdominal incision, a 21-gauge needle, 
connected to an infusion pump and a pressure transducer, was inserted into the bladder dome. 
Twenty minutes later saline infusion was initiated (6mL/h) and bladder reflex activity recorded. 
Urodynamic parameters, such as minimum and maximum bladder pressures, amplitude and 
frequency of bladder contractions were obtained using LabScribe software (iWorx; World 
Precision Instruments, UK). 
Western blot analysis 
Bladders were collected after cystometries from INT and SCT non-treated and treated 
animals. In the latter, bladders were collected and cut longitudinally in half. One portion was 
immediately frozen and stored at -80°C. The remaining hemi-bladder was collected in 4% 
paraformaldehyde (PFA), post-fixed for 5 hours and cryoprotected overnight in 30% sucrose in 
phosphate buffer with 0.1% sodium azide. Frozen samples were homogenized in lysis buffer (Tris 
50 nM, NaCl 150 nM, Triton X-100 1%, EDTA 1 nM, pH 7.6). Fifty micrograms of protein were 
separated on 12% polyacrylamide gel and transferred onto a PVDF membrane. Membranes 
were blocked for 1 hour in 5% non-fat milk in Tris-buffered saline containing 0.1% Tween-20 and 
incubated 48 hours at 4°C with primary antibodies against SNAP-25 (Synaptic Systems 111002; 
1:2000), GAP43 (Abcam ab16053; 1:200), TRPV1 (Santa Cruz Biotechnology sc-12498; 1:500) and 
VAChT (Synaptic Systems 139103; 1:1000), followed by incubation with specific horseradish 
peroxidase-conjugated antibodies. Bound antibodies were detected by chemiluminescence and 
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digital images obtained using a Chemidoc MP System Imager and the ImageLab 5.1 software 
(Bio-Rad). Membranes were re-incubated (24 hours at 4°C) with an anti-GAPDH (Abcam ab8245; 
1:10000) antibody and signal detection repeated as above. Three samples per group were 
analysed. Protein levels were quantified by densitometry using the Fiji software. All intensities 
measured were normalized against GAPDH. 
Immunohistochemical tissue analysis 
After bladder collection, SCT treated animals were perfusion fixed through the 
ascending aorta with calcium-free Tyrode's solution followed by PFA 4%. Spinal L5-S1 segments 
and adjacent dorsal root ganglia (DRG) were collected, post-fixed for 5 hours and cryoprotected 
overnight in 30% sucrose in phosphate buffer with 0.1% sodium azide. Transverse spinal cord 
and bladder 30-μm thick sections and longitudinal DRG 12-μm thick sections were obtained in a 
Leica cryostat and collected in cryoprotective solution and slides, respectively. Fixed hemi-
bladders were also sectioned in a Leica cryostat and 30-μm thick sections collected on slides. 
Alternate sections from spinal cord, bladder and DRG were thawed, thoroughly washed with 
PBS and PBST and then blocked with 10% of normal horse serum (NHS) in PBST for 1 hour. This 
was followed by a 48-hour incubation at 4°C with primary antibodies against the truncated C-
terminal peptide of SNAP-25 (1:4000; gift from Ornella Rossetto [15]), GAP43 (Abcam ab16053; 
1:5000), ATF3 (Santa Cruz Biotechnology sc-188; 1:300), CGRP (Abcam ab81887; 1:8000). After 
several washes, sections were incubated with species-specific Alexa flurocrome labelled 
antibodies (Invitrogen - ThermoFisher Scientific) for 1 hour at room temperature. The sections 
were mounted with Prolong Gold mounting medium (Molecular Probes, Porto, Portugal) and 
representative images were obtained in a Zeiss microscope (Axioimager Z1; Zeiss) using the 
Axiovision 4.8 software.  In DRG, the number of nuclei positively labelled for ATF3 was averaged 
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after counting (25-30 sections per animal). Spinal CGRP and GAP43 immunostaining was 
quantified by densitometry using the Fiji software.12 Intensity was averaged from 15 to 20 
spinal sections per animal by selecting the dorsal horn area exhibiting immunoreactivity 
(laminae I-IV), and deducting background intensity. 
Statistical analysis 
Statistical analyses were performed in GraphPad Prism 6 Software (GraphPad, San 
Diego, CA) using t-test or one-way repeated-measure analysis of variance, where appropriate, 
followed by the Tukey multiple comparison test. All values are presented as mean ± SD and 
P<0.05 was considered statistically significant. All intergroup comparisons were evaluated and 
are indicated. 
Results 
Changes in bladder innervation after spinal cord lesion 
Western immunoblotting analysis of bladder tissue from INT and 1wk and 4wk SCT 
animals demonstrated a significant decrease of SNAP-25 expression 1 week after SCT (p<0.05 vs 
spinal intact), returning to normal values when NDO is established (p<0.05 vs SCT 1 week; Figure 
1A). Similarly, levels of GAP43, a well-described marker of neuronal sprouting, were also 
decreased in bladder tissue during spinal shock (p<0.05 vs spinal intact; Figure 1B), suggesting 
some degree of denervation. Likewise, markers of sensory (Figure 1C) and parasympathetic 
fibres (p<0.01 vs INT; Figure 1D) decreased at 1-week post SCI and appeared to recover at 4 
weeks after spinal lesion. 
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Figure 1:  Changes in bladder innervation occurring after spinal cord injury. Representative Western 
immunoblotting bands and respective averaged intensities of the molecular target of Onabot/A SNAP-25 
(A; 25 kDa), the neuronal growth marker GAP43 (B; 43 kDa), and the markers of bladder sensory and 
parasympathetic cholinergic innervation, TRPV1 (C; 75 kDa) and VAChT (D; 60 kDa) obtained from bladder 
tissue of spinal intact and spinal cord injured rats 1 week and 4 weeks after lesion. cSNAP-25, cleaved 
form of synaptossome associated protein of 25 kDa; GAP43, growth-associated protein 43; INT, spinal 
intact; SCT, spinal cord transection; SNAP-25, synaptossome associated protein of 25 kDa; TRPV1, 
transient receptor potential vanilloid 1; VAChT, vesicular acetylcholine transporter. *p≤0.05 versus INT; 
#p≤0.05 versus SCT 1wk; One-way ANOVA followed by Tukey’s multiple comparison test. 
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Effects of early treatment with BoNT/A in bladder reflex activity 4 weeks after SCI 
Spinal intact rats, sham-operated, treated with saline presented a normal pattern of 
bladder reflex activity (Table 1; Figure 2A, E-H). Bladder-wall injections of BoNT/A did not 
significantly alter any urodynamic parameter evaluated in spinal intact rats 4 weeks after sham 
surgery (Table 1; Figure 2B, E-H). 
Sham + Saline Sham + Onabot/A SCT + Saline SCT + Onabot/A 
Frequency 
(contractions/ 
min) 
0.31±0.10 0.63±0.47 
0.88 ±0.24 
* 
0.92±0.42 
* 
Peak pressure 
(cm H2O) 
25.64±2.84 33.13±16.86 
40.13±6.44 
* 
37.55±8.00 
Basal pressure 
(cm H2O) 
2.89±3.24 10.25±4.11 9.75±3.67 
21.06±8.53 
*** 
# 
Amplitude 
(cm H2O) 
22.75±3.12 22.88±12.75 30.86±4.14 
16.49±6.83 
## 
Table 1: Urodynamic parameters from sham-operated and SCT rats treated during spinal shock with saline 
or Onabot/A. *p≤0.05, ***p≤0.001 versus Sham + Saline; # p≤0.05, ##p≤0.01 versus SCT + Saline; One-
way ANOVA followed by Tukey’s multiple comparison test. Onabot/A, OnabotulinumtoxinA; SCT, spinal 
cord transection. 
Rats submitted to SCT surgery and treated with saline developed the typical urodynamic 
pattern of NDO 4 weeks after lesion, characterized by high intravesical pressures (p<0.05; Table 
1; Figure 2C, F) and increased frequency of voiding contractions (p<0.05; Table 1; Figures 2C, 
H). 
Bladder injections with Onabot/A during spinal shock did not markedly affect bladder 
function in both spinal intact and SCT rats (Table 1; Figures 2D, F, H), although significant 
increase in basal bladder pressure was observed in SCT animals treated with Onabot/A in 
comparison with saline treatment (Table 1; Figures 2D, E). 
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Figure 2:  Representative cystometrograms obtained from spinal intact, sham-operated, rats treated with 
Saline (A) and Onabot/A (B) and 4 weeks after SCT rats treated with saline (C) and Onabot/A (D). Graphical 
representation of averaged basal (E) and peak (F) bladder pressures, amplitude (G) and frequency (H) of 
bladder contractions obtained for each experimental group. Graphs represent average values ± SD. 
*p≤0.05, ***p≤0.001 compared to Sham + Saline; # p≤0.05, ##p≤0.01 compared to SCT + Saline; One-way 
ANOVA followed by Tukey’s multiple comparison test. Onabot/A, OnabotulinumtoxinA; SCT, spinal cord 
transection. 
 
 
Effects of early treatment with BoNT/A in bladder tissue  
To evaluate the effects of the neurotoxin activity in the bladder, bladder histological 
sections from saline- and BoNT/A-treated SCT rats were immunoreacted against the cleaved 
form of SNAP25 (cSNAP25). Little expression of cSNAP25 was found in toxin-treated animals 
(Figure 3A). Western blot analysis of the same tissues showed similar levels of SNAP-25, GAP43, 
TRPV1 and VAChT (Figures 3B-E).  
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Figure 3:  Effects of early intravesical administration of saline and Onabot/A in bladder innervation 4 
weeks after SCT. (A) Representative image of a bladder section obtained from an SCT rat treated with 
Onabot/A showing immunoreactivity against the cleaved form of SNAP-25 (cSNAP-25). Scale bar 
represents 50μm. Representative Western immunoblotting bands and respective averaged intensities of 
the molecular target of Onabot/A SNAP-25 (B; 25 kDa), the neuronal growth marker GAP43 (C; 43 kDa), 
and the markers of bladder sensory, parasympathetic cholinergic and sympathetic adrenergic innervation, 
TRPV1 (D; 75 kDa) and VAChT (E; 60 kDa), all normalized against GAPDH (37 kDa). cSNAP-25, cleaved form 
of synaptossome associated protein of 25 kDa; GAP43, growth-associated protein 43; IR, 
immunoreactivity; Onabot/A and Onab/A, OnabotulinumtoxinA; SC, spinal cord; SCT, spinal cord 
transection; SNAP-25, synaptossome associated protein of 25 kDa; TRPV1, transient receptor potential 
vanilloid 1; VAChT, vesicular acetylcholine transporter.  
 
 
Effects of early BoNT/A treatment in lumbosacral DRG and spinal cord 
As in other studies [16], the expression of the neuronal stress marker ATF3 was 
investigated in DRG sections. The number of positive nuclei (Figures 4A, B) was similar in 
sections from SCT animals that had received either saline or BoNT/A.  
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In spinal cord sections from the same animals, the expression of the marker of neuronal 
activation c-Fos (Figure 4C), CGRP (Figures 4D-F) and GAP43 (Figures 4G-I) was also comparable 
between saline- and BoNT/A-treated SCT rats. 
Figure 4:  Effects of early intravesical administration of saline and Onabot/A in L5-S1 dorsal root ganglia 
(DRG) and spinal cord (SC) 4 weeks after SCT. (A) Representative image of an L6 DRG section from a SCT 
rat treated during spinal shock with Onabot/A showing immunoreactivity against ATF3 the transcription 
factor associated with neuronal stress in the nucleus of neurons. (B) Averaged number of ATF3 positive 
nuclei counted in DRG sections from SCT rats treated with saline or Onabot/A. (C) Averaged number of c-
Fos expressing neurons counted in SC sections from SCT rats treated with saline or Onabot/A. 
Representative images of L6 spinal cord sections showing immunorecativity against CGRP (D, E) and 
GAP43 (G, H) in the superficial lamina of the dorsal horn, where terminal of bladder sensory afferents are 
located, and averaged relative intensities of immunostaining (F, I) obtained from saline and Onabot/A 
treated SCT rats. Scale bars represent 50μm. Graphs represent average values ± SD; t test. ATF3, activating 
transcription factor 3; CGRP, calcitonin gene-related peptide; DRG, dorsal root ganglia; GAP43, growth-
associated protein 43; IR, immunoreactivity; Onabot/A, OnabotulinumtoxinA; SC, spinal cord; SCT, spinal 
cord transection. 
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Discussion 
The vast majority of SCI patients develops NDO, after an initial period of bladder 
areflexia, termed spinal shock. Treatment is, in all cases, initiated with oral antimuscarinic drugs 
and for refractory patients, the gold standard therapy relies on BoNT/A injections in several 
points of the detrusor [5, 17]. Treatment is only initiated at chronic stages of disease, but recent 
studies indicate that intervening during the spinal shock, with protocols of neuromodulation or 
antimuscarinics, may prevent NDO establishment [11-13]. Here, we tested the hypothesis that 
early intradetrusor administration of BoNT/A could also block NDO development. 
We used the rat model of large incomplete spinal transection at T8/T9, which causes 
NDO, easily identified in cystometries 4 weeks after spinal lesion [18]. We assessed the 
expression of SNAP-25, the target of BoNT/A, at different time-points after spinal lesion and 
found that spinal shock is accompanied by a significant decrease in bladder expression of SNAP-
25. Our results suggest bladder denervation and impairment of neurotransmission in the
bladder at 1 week after spinal lesion, as SNAP-25 is essential for neurotransmitter release [19]. 
Four weeks after SCI, SNAP-25 levels had increased and returned to control levels. GAP43 
expression followed a similar patter, supporting remodelling of bladder innervation as NDO 
developed. Although non-significant, bladder TRPV1 also showed a trend towards 
downregulation at spinal shock and increased expression with NDO establishment. Bladder 
levels of VAChT also reduced 1 week after SCI and approximate to control levels 4 weeks post-
SCI, being in agreement with previous observations [20]. 
The BoNT/A dosage (10 U per animal) was chosen according to a study by Behr-Roussel 
and co-workers who demonstrated long-lasting toxin effects in chronic SCI animals treated with 
10 U of BoNT/A [14]. In contrast to clinical urology [21], in the present study the toxin was 
injected during spinal shock, when the bladder is areflexic or hypocontractile and neuroplastic 
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changes leading to NDO are ongoing.  Cystometries were performed under urethane 
anaesthesia 4 weeks after surgeries and treatment. In comparison with sham animals, saline-
treated SCT rats presented evident signs of NDO, including high frequency of bladder 
contractions, and increased intravesical pressure, both at baseline and at the peak of 
contraction. Early administration of saline or BoNT/A did not affect NDO but was devoid of 
secondary effects, as it also did not affect bladder reflex activity in sham animals. The only 
urodynamic parameter affected by intradetrusor BoNT/A was basal intravesical pressures in SCT 
rats. While an increase of basal intravesical pressure would be expected reflecting the use of 
urethane anaesthesia [22], such increase was only significant in BoNT/A-treated SCT rats. The 
reason for this can only be speculated but it could reflect a combined effect of early toxin 
delivery and urethane anaesthesia. Overall, these urodynamic observations indicate that early 
administration of BoNT/A had no effect on NDO emergence. Tissue analysis confirmed a lack of 
effect of the toxin. Thus, no differences were found in the expression of SNAP25, TRPV1 and 
VAChT. Likewise, GAP43 levels were also similar in bladder samples from sham and SCT animals 
treated with saline or BoNT/A in the spinal shock period. No changes were found in the number 
of ATF3-positive nuclei in lumbosacral DRG and spinal expression of CGRP, GAP43 and c-Fos. 
As BoNT/A is the current gold-standard therapy for chronic NDO [23, 24], we 
hypothesized that early administration of the toxin would also beneficially impact on NDO 
development, in a similar fashion to what has been observed following early neuromodulation, 
oral anti-muscarinics and intravesical resiniferatoxin [12, 13, 25]. However, our results clearly 
point to a lack of toxin effect. The explanation for this could reflect the dynamics of NDO 
emergence. Indeed, one must not forget the mechanism of action of the toxin. BoNT/A is only 
internalized upon SV2 exposure during neurotransmitter release. The more active the neuronal 
terminals are, the more toxin is internalized, potentiating the intensity and extending the 
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duration of blockade of neurotransmitter release  [17]. In the present study, the toxin was 
injected 3 days after spinal lesion. As in rodents the spinal shock lasts for 10 to 14 days [18], the 
time point chosen (3 days after spinal lesion) could have been too early to prevent NDO as the 
bladder is areflexic and nerve terminals coursing the bladder wall are most likely silent. This 
likely reflects loss of supraspinal input and absence of the developing lumbosacral spinal reflex 
that will lead to NDO. Therefore, it is possible that the injected toxin was not internalized and 
could nor exert its effects on bladder fibres. Non-internalized BoNT/A is very labile and quickly 
degraded by non-specific matrix metalloproteases [26]. This hypothesis could be tested in 
subsequent experiments in which bladder injections would take place later during the spinal 
shock. 
In conclusion, although reports available in the literature have demonstrated that early 
therapeutic intervention could prevent NDO emergence, our results do not favour the use of 
BoNT/A for this purpose. However, additional experiments should be conducted at later time 
points of spinal shock, when some degree of bladder activity is already present and neuronal 
activity resumed in the bladder to fully concluded about the use of BoNT/A to harness NDO 
development. 
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Abstract
Objectives: To investigate if intravesical administration during spinal shock of
resiniferatoxin (RTX), an ultrapotent desensitizing agonist of transient receptor
potential vanilloid‐1 (TRPV1), would silence TRPV1‐expressing bladder
afferents at an early stage of disease progression and modulate neurogenic
detrusor overactivity (NDO) emergence.
Materials and Methods: Rats submitted to largely incomplete spinal cord
transection at T8/9 spinal segment were treated with intravesical RTX (50 nM)
or its vehicle during spinal shock. Four weeks after spinal lesion, bladder‐reflex
activity was evaluated by cystometry under urethane anesthesia, after which the
bladder, spinal cord, and dorsal root ganglia were collected and processed.
Results:We found improvements on bladder function several weeks after early
intravesical RTX administration, including a marked decrease of intravesical
pressures and amplitude of bladder contractions. Such strong long‐lasting
urodynamic effects resulted from the very potent desensitizing activity of RTX
on peripheral terminals of sensory afferents, an effect restricted to the bladder.
Conclusion: Our results support that an early intervention with RTX could
potentially attenuate NDO development and ensuing urinary incontinence,
with a dramatic impact on the quality of life of spinal cord injury patients.
KEYWORD S
afferent desensitization, bladder dysfunction, neurogenic detrusor overactivity, resiniferatoxin,
spinal cord injury
Abbreviations: ATF3, activating transcription factor 3; CGRP, calcitonin gene‐related peptide; DRG, dorsal root ganglia; FBS, fetal bovine serum;
GAP43, growth‐associated protein 43; GAPDH, glyceraldehyde‐3‐phosphate dehydrogenase; NDO, neurogenic detrusor overactivity; NGF, nerve
growth factor; PB, phosphate buffer; PFA, paraformaldehyde; SCI, spinal cord injury; TRPV1, transient receptor potential vanilloid‐1.
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1 | INTRODUCTION
It is well‐established that supra‐sacral spinal cord injury
(SCI) is followed by the spinal shock period during which
bladder is hypocontractile. Spinal shock is overcome by the
emergence of a new reflex pathway, totally located at the
lumbosacral spinal cord, resulting in neurogenic detrusor
overactivity (NDO).1 This condition is characterized by
increased frequency of strong involuntary bladder contrac-
tions, often causing urinary incontinence episodes.
Treatment for NDO‐induced urinary incontinence is well‐
defined and initiated by antimuscarinic drugs, with intrade-
trusor injections of botulinum toxin being the gold‐standard
treatment for refractory patients.2 However, current inter-
ventions for urinary incontinence are only introduced once
bladder dysfunction is a chronic condition, despite studies
suggesting that initiating treatment at earlier time points
could prevent bladder dysfunction and other SCI‐induced
problems. Indeed, it has been shown that pudendal nerve
stimulation and sacral neuromodulation prevents NDO in
dogs and humans3,4 and early administration of fesoterodine
to SCI rats improved bladder function several weeks after
spinal lesion.5 Together, these studies indicate that it is
possible to control NDO emergence by early interventions in
the initial stages of disease progression.
NDO is thought to result from massive neuroplastic
changes occurring in the lumbosacral spinal cord after
SCI, including sprouting of bladder afferents and
enhanced activity of transient receptor potential vanil-
loid‐1 (TRPV1)‐expressing vesical afferents.1 TRPV1 is
abundantly expressed in sensory fibers coursing the
bladder wall6 and in urothelial cells.7 Intravesical
administration of resiniferatoxin (RTX), a potent
TRPV1 agonist, induces desensitization of bladder C‐
fibers, even at very low concentrations, without produ-
cing significant noxious input.8 In SCI patients,
intravesical RTX significantly attenuated urinary in-
continence and increased bladder capacity.9 As in
animals,6 RTX‐induced improvement of bladder func-
tion was accompanied by a marked reduction in bladder
TRPV1 expression.10 In the present study, we investi-
gated if intravesical RTX administration during spinal
shock in rats submitted to spinal cord transection
would modulate NDO development.
2 | MATERIALS AND METHODS
2.1 | Animals and drugs
Experiments were performed in in‐house bred, 220 to 290 g
female Wistar rats, maintained under a 12‐hour light/ dark
schedule, with ad libitum access to food and water.
Spinal lesions or sham manipulations of the cord were
performed under deep anesthesia induced by intraperito-
neal injection of ketamine (60mg/kg) and medetomidine
(0.25mg/kg). Intravesical administration of RTX (RTX;
50 nM; Sigma‐Aldrich, Sintra, Portugal) or its vehicle (10%
ethanol diluted in sterile saline) was performed under
isoflurane anesthesia (4% for induction; 1.5% for main-
tenance). For cystometries and terminal handling, animals
received a subcutaneous injection of urethane (1.2 g/kg).
Antibodies and reagents used in cell culture experi-
ments are indicated in Table S1.
2.2 | Large incomplete spinal cord
transection and treatments
The large incomplete spinal cord transection (SCT) at
thoracic spinal segments T8/T9 was used as model of spinal
injury. After anesthesia and dorsal shaving, the T13 vertebra
was identified by palpation and the T7 to T10 vertebra
exposed. Following a laminectomy, the spinal segments T8‐
T9 were visualized and a scalpel was inserted approximately
5mm perpendicularly until the tip touched the bone. All
surgeries were performed by the same experimenter to
ensure reproducibility. The scalpel was removed and a small
piece of sterile gelfoam was inserted to limit bleeding.
Control animals underwent sham surgery and the spinal
cords left intact (INT). All animals were left to recover,
receiving daily ciprofloxacin (1mg/kg) for 10 days after
surgery. Bladders were manually emptied by abdominal
compression twice a day for a period of 2 to 3 weeks.
Animals were divided into experimental groups and
treated as described in Table 1. Solutions were slowly
injected via a urethral catheter until the bladder reached
its maximal capacity and left for 30minutes. The
concentration of RTX chosen was based in previous
studies that demonstrated clinical efficacy of a 50 nM
solution.9,11
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2.3 | Cystometries
The bladder‐reflex activity was evaluated under urethane
anesthesia with constant body temperature. Following
abdominal incision, a 21‐gauge needle, connected to an
infusion pump and a pressure transducer, was inserted into
the bladder dome. Twenty minutes later, saline infusion was
initiated (6mL/h). The urethra remained unobstructed
during cystometry and two animals from groups D and E
were removed from analysis as due to urinary retention.
Cystometric parameters were obtained from cystometro-
grams using LabScribe software (iWorx; World Precision
Instruments, Hitchin, UK). After 1‐hour‐cystometry bladders
of SCT rats treated with either vehicle or RTX, were
manually emptied and the infusion rate of saline was
increased to 10mL/h to determine the intravesical volume
necessary to induce urine release.
2.4 | Western blot analysis—bladder
tissue
Bladders were collected immediately after cystometry and
stored at −80°C until further processing. Samples were
homogenized in lysis buffer. Seventy‐five micrograms of
protein was separated on 12% polyacrylamide gel and
transferred onto a nitrocellulose membrane. Membranes
were blocked for 1 hour in 5% milk in Tris‐buffered saline
containing 0.1% Tween‐20 and incubated 48 hours at 4°C
with primary antibodies, followed by incubation with
specific horseradish peroxidase‐conjugated antibodies.
Bound antibodies were detected by chemiluminescence
and digital images obtained using a Chemidoc MP System
Imager and the ImageLab 5.1 software (Bio‐Rad, Alfragide,
Portugal). Membranes were reincubated (24 hours at 4°C)
with an anti‐GAPDH (glyceraldehyde‐3‐phosphate dehy-
drogenase) antibody and signal detection repeated as above.
Three samples per group were analysed and protocols were
repeated three times. Levels of TRPV1, calcitonin gene‐
related peptide (CGRP) and growth‐associated protein 43
(GAP43) were quantified by densitometry using the Fiji
software.12 The commercial anti‐TRPV1 antibody used in
the present study detected two bands, corresponding to
splice variants of the receptor.13 The two bands were
measured and their intensity combined. All intensities
measured were normalized against GAPDH.
2.5 | Perfusion and tissue
analysis—spinal cord and dorsal
root ganglia
After cystometry and collection of bladders, animals were
perfused through the ascending aorta with calcium‐free
Tyrode's solution followed by 4% paraformaldehyde (PFA).
Spinal L5‐S1 segments and respective dorsal root ganglia
(DRG) and the lesioned spinal cord (T8/T9) were collected,
post‐fixed for 5 hours in 4% PFA and cryoprotected
overnight in 30% sucrose in phosphate buffer with 0.1%
sodium azide. Transverse spinal cord (30‐μm thick; L5‐S1
and T8/T9) sections and longitudinal 12‐μm thick DRG
sections were obtained in a Leica cryostat (Leica, Famalicão,
Portugal). Lumbosacral spinal sections were collected in a
cryoprotective solution while DRG and T8/T9 spinal
sections were collected in Superfrost Plus slides.
As before,14 alternate sections from spinal cord and DRG
were thawed, washed and blocked with 10% of normal horse
serum (NHS) in phosphate‐buffered saline Tween‐20 (PBST)
for 1 hour. The sections were then incubated for 48 hours at
4°C in primary antibodies. After several washes, sections
TABLE 1 Experimental groups used in the present study, including the number of animals per group
Group
Surgical manipulation of
the spinal cord Intravesical treatment
Time of cystometry and tissue
collection (weeks after surgery)
A (n = 4) INT (sham surgery) None –
B (n = 4) SCT 1 wk None 1
C (n = 4) SCT 4 wk None 4
D (n = 12) SCT 4 wk Vehicle solution (10% ethanol in saline) at the
surgery day (day 0; n = 4) or at 3 and 9 d after
surgery (n = 8)
4
E (n = 12) SCT 4 wk RTX 50 nM at the surgery day (day 0; n = 4) or at
3 and 9 d after surgery (n = 8)
4
F (n = 4) INT (sham surgery) Vehicle 3 and 9 d after surgery 4
G (n = 4) INT (sham surgery) RTX 50 nM 3 and 9 d after surgery 4
Abbreviations: INT, intact; RTX, resiniferatoxin; SCT, spinal cord transection.
Note. Considering previous studies about the effects of intravesical RTX,9 à priori analysis indicated that for a power of at least 0.8, the number of animals per
experimental group should be 12. However, considering the severity of the protocols and that statistical significance was achieved with smaller number of
animals per group, the number of animals used was as shown above.
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FIGURE 1 Time‐dependent changes in bladder and spinal cord after spinal cord injury. Thionine‐stained sections from T8 spinal cord of
spinal intact (INT; A) and 4 weeks after spinal cord injury (SCT; B) rats show loss of integrity in white and gray matter as a consequence of a large
incomplete cord transection. Histological H&E‐stained bladder sections obtained from INT (C) and 4 weeks post SCT (D) rats evidence fibrosis
and an increase in bladder wall thickness related to injury. Representative cystometric recordings from INT (E) and
4 weeks post SCT (F) rats show the development of the typical NDO pattern characterized by an increased number of bladder contractions and
increased bladder pressures. Representative immunoblotting TRPV1 (75 kDa) and GAPDH (37 kDa) bands and averaged relative intensities
obtained from bladders of INT, 1 and 4 weeks post SCT show an increase in bladder TRPV1 expression 4 weeks after SCT (G). Representative
images show immunoreactivity (IR) against GAP43 (H‐J) and CGRP (L‐N) at the L6 spinal cord segment of INT, SCT 1‐week, and SCT 4‐week
rats. Respective averaged IR intensities of GAP43 (K) and CGRP (O) evidence time‐dependent sprouting of sensory afferents at the lumbosacral
cord. Graphs represent average values ± SD. GAP43, growth‐associated protein 43; CGRP, calcitonin gene‐related peptide; GAPDH,
glyceraldehyde‐3‐phosphate dehydrogenase; H&E, hematoxylin‐eosin; NDO, neurogenic detrusor overactivity; SCT, spinal cord transection;
TRPV1, transient receptor potential vanilloid‐1. *P≤ 0.05; one‐way ANOVA followed by the Tukey multiple comparison test
4 | OLIVEIRA ET AL.
100
were incubated with species‐specific Alexa flurocrome‐
labeled antibodies (Invitrogen ‐ ThermiFisher Scientific,
Porto, Portugal) for 1 hour at room temperature. DRG
sections stained for activating transcription factor 3 (ATF3)
were further incubated overnight in biotinylated IB4,
followed by PBST washes and 1‐hour incubation in
fluorochrome 488‐conjugated streptavidin. The sections were
mounted with Prolong Gold mounting medium (Molecular
Probes, Porto, Portugal) and representative images were
obtained in a Zeiss microscope (Axioimager Z1; Zeiss, Berlin,
Germany) using the Axiovision 4.8 software. Spinal CGRP
and GAP43 immunostaining was quantified by densitometry
using the Fiji software.12 Intensity was averaged from 15 to
20 spinal sections per animal by selecting the dorsal horn
area exhibiting immunoreactivity (laminae I‐IV), and
deducting background intensity. In DRG, the number of
nuclei positively labelled for ATF3 was averaged after
counting (25‐30 sections per animal). Spinal T8/T9 cord
sections were stained using the thionine protocol to analyze
lesion extension.
Bladders obtained from INT and 4‐week‐SCT animals
were washed in PBS at 4°C for 7 hours and fixed in 10%
buffered formalin for 24 hours. After paraffin embedding,
bladders were sectioned at 5 mm and stained with
hematoxylin‐eosin to analyze tissue histology.
2.6 | In vitro studies: DRG cell culture
After cystometry, L5‐S1 DRG were collected from vehicle
and RTX‐treated SCT animals (n= 3 per group) and placed
in Dulbecco’s modified Eagle’s medium‐F12 (10% fetal
bovine serum [FBS] and 1% penicillin/streptomycin). Cell
culture was done as in other studies14 and included a
digestion with 0.125% collagenase (2 hours at 37°C), tissue
dissociation, purification, and duplicate cell plating onto
poly‐L‐lysine and laminin‐coated coverslips, maintained at
37°C in a humidified 5% CO2 atmosphere for 12 hours. This
was followed by fixation with ice‐cold 4% PFA for
15minutes, several washes and incubation for 5minutes in
0.1% of sodium borohydride. After PBS washes and 1‐hour
blocking with 5% FBS in 0.4% PBS‐Tween‐20, cells were
incubated in anti‐β3‐tubulin antibody, with subsequent
washes and further incubation with a species‐specific
Alexa Fluorochrome‐labeled antibody. Coverslips were
mounted with Vectashield medium (Vector Laboratories,
Peterborough, UK) and images collected in an Axioskop 40
microscope with the AxioVision 4.6 Software (Carl Zeiss) for
quantification of neurite branching and total neurite length
analysis with SYnapse Detector (SynD).
2.7 | Statistical analysis
Statistical analyses were performed in GraphPad Prism 6
Software (GraphPad, San Diego, CA) using a t test or one‐
way repeated‐measure analysis of variance; followed by
the Tukey multiple comparison test. All values are
presented as mean ± SD and P< 0.05 was considered
statistically significant. All intergroup comparisons were
evaluated and are indicated.
3 | RESULTS
3.1 | Largely incomplete spinal cord
transection alters bladder function and
histology
Histological analysis of the spinal T8/T9 segments and
bladders obtained from groups A‐C showed evident
TABLE 2 Cystometric findings from intact and SCT rats after early treatment with vehicle and RTX
Frequency of
voiding
contractions (no. of
contractions/min)
Frequency of
voiding
contractions (no. of
contractions/min)
Baseline pressure
of voiding
contractions, cm
H2O
Peak pressure of
voiding
contractions, cm
H2O
Amplitude of
voiding
contractions, cm
H2O
Intact + vehicle 0.37 ± 0.13 0.21 ± 0.02 3.50 ± 2.80 28.01 ± 3.96 24.51 ± 3.44
Intact + RTX 0.54 ± 0.05 0.02 ± 0.02 18.17 ± 5.21 37.40 ± 4.54 19.23 ± 6.31
****P< 0.0001
SCT + vehicle 0.71 ± 0.20*** 0.44 ± 0.14 11.59 ± 5.37 42.44 ± 9.81 34.03 ± 9.83
***P= 0.0006 **P= 0.0100 **P= 0.0012 ***P= 0.0006 *P= 0.0223
$P= 0.0456 $$P= 0.0032
SCT +RTX 0.46 ± 0.16 0.11 ± 0.07 14.00 ± 2.48 31.93 ± 5.28 18.89 ± 2.76
##P= 0.0086 ####P< 0.0001 ****P< 0.0001 ##P= 0.0088 ###P= 0.0001
Abbreviations: RTX, resiniferatoxin; SCT, spinal cord transection.
Note. Data presented as mean ± standard deviation.
*P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, and ****P≤ 0.0001, compared to Intact + Vehicle group.
##P≤ 0.01 and ###P≤ 0.001, compared to SCT+Vehicle group.
$P≤ 0.05 and $$P≤ 0.01, compared to Intact + RTX group.
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changes after spinal lesion. Four weeks post lesion there
was an almost entire loss of gray‐matter arrangement in
dorsal and ventral horns, with white‐matter disruption
and several cavities (Figure 1B) absent in sections from
spinal intact (Figure 1A). These histological changes are
consistent with a large incomplete spinal transection as
spared tissue was present in most sections obtained from
the lesioned area, albeit in very small quantities at some
places. At the same time points, histological changes
were also present in bladder sections with a significant
increase in bladder wall thickness (629.7 ± 331.1 μm in
spinal intact animals and 1236 ± 117.4 μm at 4 weeks post
SCI; P= 0.021) (Figure 1C,D).
Spinal T8/T9 injury induced marked changes in
bladder function, with increased frequency of bladder
contractions and higher peak pressures (Figure 1E,F).
These changes were accompanied by a significant time‐
dependent increase in bladder TRPV1 and lumbosacral
spinal GAP43 and CGRP expression (Figure 1 G‐O; Table
S2; P< 0.05 vs spinal intact).
FIGURE 2 Continued.
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3.2 | Early RTX administration
improves bladder function in chronic SCT
animals
All animals were daily evaluated after spinal lesion and
submitted to abdominal compression for urine removal.
There were no changes in the duration of the spinal
shock period that could be attributed to intravesical
treatment.
Vehicle‐treated INT animals presented normal blad-
der‐reflex activity without any major change in any
cystometric parameter (Table 2; Figure 2A,E‐H). INT rats
that received intravesical RTX presented a significant
increase in basal pressure (P< 0.001; Table 2; Figure
2B,E‐H).
Four weeks after SCT, vehicle‐treated rats presented
urodynamic patterns indicative of NDO and similar to
nontreated SCT animals (Table 2 and Figure 2C,E‐H),
with significant increases in all parameters analysed.
Early intravesical RTX administration significantly im-
proved bladder activity in SCT rats, irrespective of the day
of intravesical treatment or the number of RTX instilla-
tions (Table 2 and Figure 2D,E‐H).
Changes in volume of infused saline necessary to
induce an expulsive bladder contraction were also
found following early RTX. In SCT animals treated
with early vehicle the infused volume necessary to
induce urine release was 0.94 ± 0.034 mL and voiding
occurred 5.66 ± 2.07 minutes after the beginning of
accelerated saline infusion. In SCT rats treated with
early RTX those values changed to 3.30 ± 0.60 mL
(P= 0.0018 vs vehicle) and 20.23 ± 3.38 minutes
(P= 0.0013), respectively.
3.3 | Early RTX administration after
spinal cord injury reduces bladder TRPV1,
CGRP, and GAP43 expression without
changing histology
Four weeks after SCT and early RTX administration,
TRPV1 expression in the urinary bladder had decreased
by 42% (Figure 2K; P= 0.0142 compared to vehicle‐
treated animals). In contrast, gross bladder histology was
not altered by the treatment (Figure 2I,J). The reduction
in TRPV1 expression was accompanied by a significant
reduction in the CGRP and GAP43 content (respectively,
64% and 44% decrease compared to SCT vehicle‐treated
animals; P= 0.0293 and P= 0.0441; Figure 2L,M).
3.4 | Early intravesical administration
of RTX does not induce neuronal injury in
lumbosacral DRG neurons
As RTX‐induced reduction of bladder GAP43, TRPV1,
and CGRP expression could reflect long‐term injury to
bladder afferents, the expression of the well‐established
marker of neuronal stress ATF315 was resolved by
immunohistochemistry in sections from L5‐S1 DRG,
where perikarya of bladder afferents are located. Expres-
sion of ATF3 was found in the nuclei of a small number
of DRG neurons, which lacked CGRP expression and did
not bind IB4 ( Figure 3A‐C). No differences were found
between the number of ATF3‐positive nuclei between
vehicle‐treated (1.21 ± 0.57) and RXT‐treated SCT rats
(1.84 ± 1.19; Figure 3D).
Effects of early RTX on the intrinsic growth ability of
DRG neurons, a measure of neuronal viability, were also
FIGURE 2 Effects of early intravesical administration of vehicle and RTX in bladder function, morphology and innervation 4 weeks after SCT.
Representative cystometric recordings from spinal intact (INT) and 4 weeks SCT animals treated with early vehicle (A and C, respectively) and RTX
(B and D, respectively) show that the typical pattern of NDO is present in vehicle‐treated 4‐week SCT rats but absent in SCT animals that received
early RTX. Red arrows indicate representative voiding contractions and blue arrows show representative nonvoiding contractions. The amplitude of
bladder contractions was calculated by subtracting minimal to maximal pressure values. Frequency was calculated as the number of bladder
contractions with amplitude values greater than 10 cm H2O occurring in a period of 30minutes.
14 Graphics show average basal (E) and peak
(F) pressures, amplitude (G) and frequency (H) of bladder contractions from all experimental groups and demonstrate a significant decrease in peak
pressure, resulting in a marked decline of the amplitude of bladder contractions, and a reduction in frequency of voiding contractions following early
RTX. Histological H&E‐stained bladder sections obtained from 4‐week SCT rats treated with vehicle (I) and RTX (J) evidence no alterations in
bladder morphology related to treatment. Representative immunoblotting bands corresponding to TRPV1 (75 kDa) and GAPDH (37 kDa) in the
bladder of 4‐week SCT animals treated with vehicle (Ve) and RTX and averaged relative intensities (K) show a significant decrease in bladder TRPV1,
the receptor for RTX, after early treatment with the toxin. Likewise, CGRP (15 kDa; L) and GAP43 (43 kDa; M) immunoblotting bands and averaged
immunoreactivity intensities indicate a strong decrease in sprouting of peptidergic sensory bladder afferents following early treatment with RTX.
Graphs represent average values± SD. ANOVA, analysis of variance; CGRP, calcitonin gene‐related peptide; GAP43, growth‐associated protein 43;
GAPDH, glyceraldehyde‐3‐phosphate dehydrogenase; H&E, hematoxylin‐eosin; NDO, neurogenic detrusor overactivity; RTX, resiniferatoxin;
SCT, spinal cord transection; TRPV1, transient receptor potential vanilloid‐1. In graphs E‐H *P≤ 0.05, **P≤ 0.01, and ***P≤ 0.001 compared to INT
and ##P≤ 0.01, ###P≤ 0.001 compared to SCT+Vehicle; one‐way ANOVA, followed by the Tukey multiple comparison test. In graphs K‐M,
*P≤ 0.05; t test
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evaluated in in vitro conditions with abundant concen-
tration of nerve growth factor (NGF) in the medium. All
L5‐S1 DRG neurons collected from vehicle‐ or RTX‐
treated SCT animals attached to the substrate and
emitted long neurites (Figure 3 E,F). No differences were
found between groups in the average length of neurites
(5.01 ± 0.72mm and 4.83 ± 0.21mm, respectively in
vehicle‐ and RTX‐receiving rats) or neurite branching
(Figure 3G,H).
3.5 | Early intravesical RTX
administration does not alter spinal
expression of CGRP and GAP43
To investigate the effects of early RTX at the lumbosacral
(L5‐S1) spinal cord, where the majority of bladder afferents
central projections terminate, spinal expression of CGRP
and GAP43 was resolved. Intense CGRP immunolabeling in
the superficial laminae of the cord was observed (Figure
3I,J), with some processes present in deeper laminae.
GAP43 was also found in laminae I‐II (Figure 3L,M) but not
in deeper areas of the cord. In both cases early RTX did not
change spinal expression of these proteins (Figure 3 K,N).
4 | DISCUSSION
Management of SCI‐induced urinary incontinence has
always been focused on dealing with a chronic condition
rather than attempting to harness its development.16
Recent studies, however, suggest that early interventions
are of clear benefit for SCI patients whether they aim to
reduce pain and spasticity17,18 or improve bladder
function.3,4 Accordingly, here we found that early
intravesical RTX administration significantly attenuated
NDO development, acting in peripheral structures with-
out effects on spinal afferent terminations.
In the present study, we used a rodent model of
largely incomplete spinal transection. The concentration
of RTX used (50 nM) had already been shown to
be effective in reducing bladder hyperactivity.9,11
Administration of this neurotoxin was performed during
spinal shock, when the bladder is areflexic or hypocon-
tractile and it is assumed that neuroplastic changes
leading to NDO are occurring.1 Four weeks after
treatment and irrespective of the time of intravesical
treatment or the number of exposures to RTX, improve-
ment of bladder function was evident and still present 8
weeks after treatment (data not shown), in agreement
with other studies.19 This is an important outcome which
indicates that early intravesical RTX administration may
mitigate the development of high intravesical pressures
in a long‐lasting manner, an important matter in NDO
management.20 Importantly, we found an increase in
basal intravesical pressures after RTX treatment, suggest-
ing urinary retention, which, in patients could concur to
reduce urinary incontinence, provided patients are
following a clean intermittent catheterization regime for
timely urine removal. However, it should be recalled that
this this observation could merely reflect the effects of
urethane,21 as cystometries were performed under
anesthesia.
As in SCI patients,22 bladder TRPV1 was upregulated
following largely incomplete spinal transection. TRPV1
overexpression was significantly reduced after early
intravesical RTX, despite treatment having taken place
4 weeks earlier. These observations agree with previous
studies demonstrating decreased TRPV1 bladder levels as
early as 24 hours posttreatment6 and indicate that RTX
effects on the expression of its receptor are long‐lasting.19
In the urinary bladder, TRPV1 strongly colocalizes with
CGRP.6 Accordingly, CGRP levels were also reduced
following early intravesical RTX treatment, confirming
the effect this neurotoxin on peptidergic fibers.6
Like TRPV1 and CGRP, the expression of axonal growth
GAP43 was decreased in the bladder following early RTX. It
is likely that improvement of bladder function by early RTX
could have resulted from blocking axonal expansion of
peptidergic terminals in the bladder wall, possibly reflecting
decreased NGF content in the bladder wall.23 The reasons
for this could reside in the well‐known effect of vanilloids
on axonal transport.24 Our cell culture experiments suggest
FIGURE 3 Effects of early intravesical administration of vehicle and RTX in lumbosacral DRG and spinal cord 4 weeks after SCT.
Representative images show immunofluorescence staining for the neuronal stress marker ATF3 (red) and CGRP or IB4 (green) in the
lumbosacral DRG from SCT rats treated with vehicle (A) and RTX (B, C). ATF3 expression is restricted to the nuclei of cells and no positive
nuclei is found in CGRP‐immunoreactive and IB4‐binding perikarya. No differences were found between treatments, suggesting that
neurons did not suffer any injury related with intravesical treatment (D). When cultured in controlled conditions with abundant NGF, DRG
neurons collected from SCT animals receiving early vehicle (E) or RTX (F) show a similar pattern of neurites extending (G) and ramification
(H) irrespective to treatment, as shown by anti‐β3‐tubulin immunostaining. Representative images show a similar pattern of CGRP (I,J) and
GAP43 (L, M) immunoreactivity in the superficial lamina of dorsal horns of L6 spinal cord segments obtained from vehicle‐RTX‐treated rats.
No changes on immunoreactivity intensities of CGRP (K) and GAP43 (N) were found after early administration of RTX. Graphs represent
average values ± SD; t test. ATF3, activating transcription factor 3; CGRP, calcitonin gene‐related peptide; DRG, dorsal root ganglia; GAP43,
growth‐associated protein 43; NGF, nerve growth factor; RTX, resiniferatoxin; SCT, spinal cord transection
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that NGF deprivation due to impaired transport might
indeed be involved in reduced axonal sprouting following
early RTX as DRG neurons collected from vehicle‐ and
RTX‐treated SCT animals presented similar patterns of
axonal branching when cultured in controlled conditions
with abundant NGF.
As the effects on bladder function were evident at 4
weeks after RTX, we hypothesized that the toxin might
have induced damage to DRG neurons. To investigate
this, we evaluated the expression of ATF3, an established
marker of neuronal response to peripheral injury.15 We
found ATF3‐positive nuclei in sections from both vehicle
and RTX‐treated SCT animals. ATF3 levels were similar
between groups, indicating that the putative neurotoxic
effects were not reflected in ATF3 expression. Although
this might suggest that RTX did not induce a severe
injury to DRG neurons, 4 weeks might be enough time to
resolve whichever neuronal damage might have been
induced by RTX. In fact, it should be noted that at the
same time point following RTX instillation the expression
of the injury markers galanin and c‐Jun in DRG neurons
had already returned to control values.25
In contrast to the bladder, no changes were seen in
CGRP and GAP43 levels at the lumbosacral spinal cord.
The reasons for this may only be speculated but it is
possible that intravesical RTX could have blocked traffick-
ing of CGRP and GAP43 from the cell bodies to the bladder,
without affecting trafficking to the central processes
terminating in the dorsal horns. This is in line with studies
demonstrating a reduction in the expression of bladder
CGRP following peripheral colchicine treatment without
changes in the lumbosacral spinal CGRP expression.26
Altogether, results presented support the benefits of early
intravesical administration of RTX to attenuate NDO
development. Our data adds to the growing body of
evidence3-5 that postulates that the anticipation of therapeutic
intervention might avoid degradation of bladder function,
with a clear positive impact on the SCT patients’ quality of
life.
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1. Improving treatment of NDO: the use of BoNT/A
Since the first application of BoNT/A in clinical urology [1], the toxin has been extensively 
studied being currently recognized as an effective and powerful therapeutic tool. It is  an 
established and licensed therapy for neurogenic detrusor overactivity (NDO) and  idiopathic 
overactive bladder (OAB) and it is also used off-license in the treatment of bladder pain 
syndrome (BPS), DSD and benign prostatic hyperplasia (BPH) [2, 3]. Improvements in urinary 
function and reduction of pain levels reflect toxin-mediated blockade of neurotransmission, 
affecting both efferent and afferent neuronal pathways that control LUT function [4, 5]. BoNT/A 
wide-ranging, long-lasting but reversible effects on LUT innervation, adding to its safe 
administration and rare secondary effects support its wide use in clinical urology [6]. 
1.1. Conversion of Onabot/A and Abobot/A for bladder wall injections (Publication I) 
Multiple toxin formulations are currently commercially available from different vendors 
[7], although Onabot/A has been the most well-studied and most commonly used in clinics [8]. 
Onabot/A is the only formulation of botulinum toxin A approved by competent authorities for 
management of specific LUT pathologies, with dosages of 100 U and 200 U indicated for OAB 
and NDO [5]. Abobot/A is also frequently used in clinical urology, albeit in off-label conditions. 
This formulation is currently in phase 3 clinical trials for the management of neurogenic bladder 
[9]. 
All formulations of BoNT/A include the 150 kDa neurotoxin domain, responsible for the 
catalytic effect on SNAP-25 but the amount of the active toxin in Onabot/A and Abobot/A 
commercial vials differ. While flasks of Onabot/A contain 0.9 ng, the Abobot/A containers hold 
2.69 ng [10]. This difference results from the presence of structural accessory proteins, 
necessary to stabilize the toxin. Thus, the molecular weight of Onabot/A is 900 kDa and of 
Abobot/A is 500 kDa [11]. The recommended dosages for each formulation are defined with 
bioessays, but companies have used different analytical methods. Therefore, it is difficult to 
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determine an equivalence between unitary doses of toxin formulations [11]. Although Onabot/A 
potency is determined by the EC50 (amount of toxin required to provoke a response halfway 
between the baseline and the maximum response) of cSNAP-25 in differentiated neuroblastoma 
cells, Abobot/A potency is determined by the mouse LD50 (amount of toxin that kills 50% of the 
mice) [12-14]. Because it may be important in the clinical setting to choose between Onabot/A 
and Abobot/A, some studies compared the effects of unitary doses of toxins formulations in 
skeletal muscle [8, 15, 16]. In the bladder, some works suggested dose equivalence ratios varying 
between 1:3 to 1:5 Units of Onabot/A and Abobot/A, but results were not thoroughly confirmed 
and often challenged by other investigators [17, 18]. 
The first publication included in this dissertation (Publication I) addresses this issue and 
aimed to accurately identify a dose conversion ratio for Onabot/A and Abobot/A for bladder 
smooth muscle injections. Our experimental procedure consisted of injecting the same amount 
of Onabot/A and Abobot/A, diluted in equal saline volume, in a single apical point of the mouse 
bladder dome. The relative potency for each formulation was evaluated based on its catalytic 
capacity and the number of bladder fibres expressing the cleaved form of SNAP-25 was counted. 
The main finding of our study was that Onabot/A is 1.6 times more efficient than Abobot/A, 
when targeting bladder nerve fibres and cleaving SNAP-25. As Onabot/A is commercially 
available in vials of 50 U and 100 U while Abobot/A flasks contain 500 U, the results presented 
in Publication I indicate that the Onabot/A formulation might be easier to use and to adjust the 
amounts needed, in order to avoid overdosing. In fact, the use of excessive doses of Abobot/A 
in clinic urology, when converting amounts between the two formulations, might underlie the 
reported higher rates of severe urinary retention in comparison to Onabot/A [17]. Overdosing 
should be avoided to minimize kidney damage due to urinary retention and to decrease 
probabilities of developing antibodies against BoNT/A that compromise treatment efficacy [19]. 
In this study, the diffusion pattern was also observed as spread of the injected volume 
could reflect on the effects of the toxin on bladder contractibility. Studies from other groups 
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suggested limited spread from the site of injection, exclusively dependent on the volume 
injected [15, 20]. Thus, dilution of BoNT/A products should be considered based on the area of 
the muscle to treat [21]. Here, the dose of 0.5 U of toxin formulations was diluted in a total 
volume of 2 µL of saline, which was chosen based on toxin ability to cleave SNAP-25. However, 
irrespective of the BoNT/A formulation, the number of cSNAP-25 expressing fibres was variable 
among experimental animals injected. We propose that the fluctuations observed are due to 
inevitable errors associated with one unique injection in a particularly thin bladder wall of mice. 
As these fluctuations also reflect the experimenter’s dexterity, this should be considered in 
clinical practice, where the procedure often consists in 20 to 30 bladder injections [22]. 
Importantly, accurate therapeutic dosages of each one of the formulations should be 
further evaluated in the scope of different pathological conditions in experimental animals and 
human patients, once physical spread, passive diffusion and migration through axonal or 
haematogenous transport cannot be disregarded as contributors to toxin’s efficacy and 
adversities [23]. 
1.2. Effect of intrathecal BoNT/A in chronic NDO as an alternative for bladder injections 
(Publication II) 
Pioneer works from Schurch and co-worker demonstrated that intradetrusor injection 
of  Onabot/A improved bladder function and abolished urinary urgency in neurogenic patients 
[24, 25]. Subsequent studies confirmed and expanded these initial observations and in 2011 
bladder injections of Onabot/A were licensed by the FDA for the treatment of NDO [26-29]. 
Today, intradetrusor Onabot/A is the gold standard option for patients that are refractory to 
oral medication [5]. Treatment efficacy relies on the toxin ability to block neurotransmission in 
bladder nerve fibres. Urodynamic evaluation of patients following treatment clearly shows long-
lasting improved bladder function, with a marked reduction in bladder contractions and in the 
number of UI episodes, still present 6 to 9 months after treatment [26, 27, 30]. 
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BoNT/A is a non-specific neurotoxin and targets the different nerve fibres coursing in 
the bladder wall. The high affinity toxin receptor SV2 is present in 95% of parasympathetic, 69% 
of sympathetic and 58% of sensory bladder fibres [31, 32]. Following bladder injection, the 
cleaved form of SNAP-25, a marker of the proteolytic activity of the neurotoxin, was present in 
all fibres [33], but predominantly in cholinergic and sensory fibres in detrusor and suburothelial 
bladder layers [31]. Therefore, reduction in urgency and bladder contractions after BoNT/A 
delivery most likely reflects the effect of the neurotoxin in blocking release of acetylcholine from 
cholinergic nerve terminals and activation of muscarinic receptors in smooth muscle cells [34]. 
Because urothelial cells are also able to release acetylcholine [35], this does not exclude an effect 
on the urothelium [36, 37]. However, excessive inhibition of parasympathetic neurotransmission 
could result in urinary retention, a problem referred by some patients [28]. 
The contribution of efferent neuronal pathways to the establishment of NDO seems to 
be limited and the leading role is played by afferent C-fibres, which undergo sprouting at the 
lumbosacral spinal cord [38]. This results in massive spinal synaptic rearrangement and, 
ultimately, in a new spinal circuit, responsible for abnormal bladder function. Therefore, one 
can hypothesize that targeting bladder C-type afferents at the spinal cord level could be 
beneficial and reduce urinary dysfunction after SCI. This is supported by a study demonstrating 
that intrathecal administration of BoNT/A improved bladder reflex activity and reduced pain in 
an animal model of chronic cystitis by specifically targeting peptidergic afferents [39]. Therefore, 
in Publication II we explored the intrathecal route for BoNT/A administration as a way of 
specifically blocking bladder sensory afferents in animals SCI-induced NDO and assessed the 
effects on bladder reflex activity. 
The rat model of thoracic spinal cord complete sectioning was used and animals 
presented evident signs of NDO 4 weeks after lesion (increased intravesical pressures and 
frequency of bladder contractions) [38, 40]. Such urodynamic changes were accompanied by 
sprouting of peptidergic sensory afferents at the L5-L6 lumbosacral spinal cord, and increased 
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expression of calcitonin gene related peptide (CGRP), as also observed by others [41]. As before, 
[39], 5 units of BoNT/A, diluted in 50 μL of saline, were injected in the intrathecal space of 4-
week SCI animals. This resulted in improved bladder reflex activity, with significant decrease in 
voiding frequency and bladder basal pressures. This was accompanied by marked cleavage of 
SNAP-25 mainly in laminae I and II of the spinal L5-6 and a significant reduction in CGRP 
expression at lumbosacral spinal cord and DRG in response to IT Onabot/A, suggesting an effect 
of the toxin on peptidergic sensory afferents. 
While BoNT/A effects on bladder efferent nerves have been widely studied and are 
particularly well described, effects on sensory afferents are less well understood [42]. Together 
with previous studies [39], these observations indicate that BoNT/A-mediated improvement of 
bladder function in pathological conditions may result from the effects of the toxin on sensory 
fibres. Accordingly, ATF3, a marker of cellular injury, was found in the nuclei of DRG neurons. 
CGRP expression in the soma of DRG neurons was also affected. Together, these results suggest 
that BoNT/A-mediated improvement of bladder function in pathological conditions may also 
results from an effect on sensory fibres without affecting efferent nerves and causing urinary 
retention. In the future, NDO management might be improved by restricting the action of this 
toxin to sensory afferents, possibly by producing recombinant botulinum toxins. 
2. Can NDO be prevented?
NDO is very common amongst SCI patients, affecting approximately 90% of individuals 
with high thoracic lesions [43-45]. Initially, during spinal shock, management of urinary 
dysfunction aims to guarantee bladder emptying. When this is overcome and NDO has emerged, 
additional treatments initiate with the goal of reducing the frequency and/or intensity of 
bladder contractions and, if present, control DSD  [46, 47]. This results in control of urinary 
incontinence and intravesical pressures. Of note, treatment is only initiated when NDO is a 
chronic, established condition, with little chances of reverting to a more favourable situation. 
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While the current approach consists in waiting for the disorder to develop and then initiate 
treatment, a new trend has been attracting increasing attention. Because prevention is always 
better than cure, some studies have sought to investigate if NDO emergence can be blocked. 
Sievert and co-workers were pioneers in the field, initiating sacral neuromodulation during 
spinal shock. Twenty-six months after electrode implantation, they found that early treatment 
prevented NDO and urinary incontinence [48]. Similar observations were made in a dog model 
of SCI [49]. More recently, Biardeau and co-workers demonstrated that administration of 
fesoterodine, a well-established antimuscarinic drug, initiated immediately after experimental 
spinal injury and lasting for 6 weeks, had beneficial effects on bladder function, with a significant 
reduction of intravesical pressures in treated SCI rats [50]. This suggest that early interventions 
might be used to prevent NDO and protect the urinary tract. These observations are in line with 
other studies, where treatment was also initiated at very early stages of neuronal injury 
progression, that demonstrated a positive impact on pain and spasticity  [51, 52]. 
2.1. Effects of early bladder injection of BoNT/A in SCI rats (Unpublished observations) 
BoNT/A has been in the spotlight of neurourology research for several years, and the 
toxin effectiveness in managing bladder hyperactivity has been proved in several research 
projects and numerous clinical trials [2, 3]. Bladder wall injections of Onabot/A are currently 
licensed for the management of NDO in SCI patients that do not respond to oral antimuscarinic 
drugs. Still, treatments initiate in a chronic phase post-injury, when NDO is already settled. With 
focus on risks of periodical increments in intravesical pressures and undesirable situations of 
urinary incontinence, we considered important to evaluate the toxin capacity to prevent NDO, 
rather than treating it during chronic stages. 
We treated SCI rats with intra-detrusor Onabot/A 3 days after lesion and evaluated 
cystometric activity 4 weeks after. Our results suggested that when administered in a so early 
time-point after SCI, the toxin is unable to induce any significant improvement in bladder 
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function, with SCI rats developing NDO 4 weeks after lesion. This contrasts with toxin’s proven 
efficacy in managing chronic NDO in experimental animals [53] and patients [22, 25-28]. 
Corroborating functional data, no alterations were found in bladder and lumbosacral spinal cord 
innervation as well as DRG neurons after the early treatment with the Onabot/A. 
Our findings diverge from those from Temeltas and co-workers [54], demonstrating that 
BoNT/A improved basal pressure, frequency and amplitude of inhibited detrusor contractions in 
SCI rats, when administered 7 days after SCI.  Accordingly, we might infer that bladder areflexia 
is accompanied by denervation and loss of neuronal activity, as suggested by the analysis of 
SNAP-25, GAP43, TRPV1 and VaChT in the rat bladder 1 week after SCI, which limits toxin 
internalization. Thus, a reasonable hypothesis is that 7 days after injury some regenerative 
mechanisms might start to occur, which guarantee a higher rate of toxin internalization and 
potentiate bladder effects. This remains to be explored and additional studies are needed. 
2.2. Effects of early intravesical administration of RTX in SCI rats (Publication III) 
Emergence of NDO is known to reflect massive neuroplastic events catalysed by spinal 
injury. The current paradigm assumes that during spinal shock the levels of nerve growth factor 
(NGF) increase in the bladder and spinal cord. This neurotrophin induces sprouting of TrkA-
expressing bladder C-type sensory fibres, which greatly expand their peripheral and central 
processes. At the spinal cord, these afferents establish new synaptic contacts and a new 
micturition reflex is formed, restricted to the spinal cord and responsible for abnormal bladder 
function and/or DSD [55, 56]. 
Bladder C-type fibres are critical to NDO development and maintenance. The majority 
of these fibres express the TRPV1 receptor [57] and its expression is known to increase in NDO 
patients [58, 59]. Strong agonists of TRPV1, including RTX, have been used in the past to treat 
chronic NDO. These agonists are known to cause desensitization of TRPV1 [60] and, 
consequently, silence bladder afferents. Accordingly, intravesical administration of RTX is known 
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to reduce the number of incontinence episodes and increase bladder capacity in NDO patients 
[61-63]. Therefore, we questioned if, like sacral neuromodulation and anticholinergics, early 
intravesical administration of RTX would impact NDO development. 
In Publication III, animals received intravesical RTX during spinal shock and bladder 
function was evaluated 4 weeks after spinal lesion and treatment. Bladder reflex activity was 
markedly better in RTX-treated SCI animals in comparison with animals receiving vehicle 
solution. Improvement of bladder function resulted from a restricted effect to the bladder, 
where expression of TRPV1, CGRP and GAP43 were reduced. In DRG and spinal cord, no major 
changes were observed. Moreover, no obvious signs of neuronal stress were found, as DRG 
neurons had very low levels of the stress marker ATF3 and presented normal growth capacity 
when in in vitro conditions. Thus, results presented in Publication III support that early 
administration of RTX can attenuate NDO development without any major deleterious 
secondary effects, as this neurotoxin only acted on the bladder. Moreover, these results also 
concur to a shift in the paradigm of NDO treatment, anticipating interventions rather than only 
acting when NDO is a fixed condition, with little chances to change. 
Interestingly, our results indicate that early intervention with RTX is more effective than 
with BoNT/A, which failed to produce any effect on NDO development. Our observations 
contrast with those from a randomized study including 25 chronic NDO patients, which 
demonstrated better clinical and urodynamic outcomes following  treatment with BoNT/A, 
when compared to RTX [64]. The reasons behind those contradictory results can only be 
speculated at present but might reside on the mechanisms of action of each neurotoxin. While 
BoNT/A-mediated impairment of neurotransmission requires active axonal terminals, exposing 
synaptic proteins upon vesicle fusion, RTX binds to TRPV1 receptors whether expressing fibres 
are active or silent. During spinal shock, when the bladder is arreflexic, the majority of bladder 
fibres are silent. Thus, following intradetrusor injection, BoNT/A fails to be internalized and is 
quickly degraded by extracellular matrix proteases [65]. On the other hand, although BoNT/A is 
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able to target a larger population of bladder fibres [32], intravesical administration of TRPV1 
targets nerve fibres and TRPV1-expressing urothelial cells [36, 37] and the net-effect of RTX-
induced desensitization does not depend on the activity of TRPV1-expressing structures. 
Therefore, pending additional studies, RTX might be preferable for early treatments aiming to 
harness NDO development. 
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Conclusions 
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All studies included in this dissertation aimed to improve NDO treatment and to investigate 
if NDO can be prevented. Work focused on two well-known neurotoxins: BoNT/A, the current 
gold-standard treatment, and RTX, a plant-derived neurotoxin. The main findings of these 
studies are:  
1. The dose conversion ratio for bladder wall injection of Onabot/A and Abobot/A should
be 1 U of the first for each 1.6 U of the latter. 
2. Effectiveness of Onabot/A and Abobot/A treatment is dependent on variability in
BoNT/A bladder wall injections, which is likely overcome by numerous injection points, and 
spread of the toxin across tissue. 
3. Intrathecal administration of Onabot/A improves urodynamic pattern of neurogenic
bladder after SCI. This route for toxin administration specifically modulates afferent sensory 
neurons and spares efferent remaining activity. 
4. Early administration of intradetrusor BoNT/A does not affect NDO development, which
was present in control and treated SCI animals. 
5. Intravesical administration of RTX during spinal shock successfully attenuates NDO
emergence, without secondary effects. Together with observations in point 4 and pending 
further investigation, it may be possible that intravesical RTX could be a better choice to harness 
NDO development.  
123
124
References in Final considerations
[1] B. Schurch, D. Hauri, B. Rodic, A. Curt, M. Meyer, A.B. Rossier, Botulinum-A toxin as a 
treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury 
patients, The Journal of urology, 155 (1996) 1023-1029. 
[2] D. Eldred-Evans, P. Dasgupta, Use of botulinum toxin for voiding dysfunction, Transl Androl 
Urol, 6 (2017) 234-251. 
[3] J.F. Jhang, H.C. Kuo, Botulinum Toxin A and Lower Urinary Tract Dysfunction: 
Pathophysiology and Mechanisms of Action, Toxins, 8 (2016) 120. 
[4] S. Malde, C. Fry, B. Schurch, T. Marcelissen, M. Averbeck, A. Digesu, A. Sahai, What is the 
exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of 
overactive bladder/detrusor overactivity? ICI-RS 2017, Neurourology and urodynamics, 37 
(2018) S108-S116. 
[5] Y.H. Jiang, C.H. Liao, H.C. Kuo, Current and potential urological applications of botulinum 
toxin A, Nature reviews. Urology, 12 (2015) 519-533. 
[6] D. Dressler, Clinical applications of botulinum toxin, Curr Opin Microbiol, 15 (2012) 325-336. 
[7] S. Samizadeh, K. De Boulle, Botulinum neurotoxin formulations: overcoming the confusion, 
Clin Cosmet Investig Dermatol, 11 (2018) 273-287. 
[8] A. Ferrari, M. Manca, V. Tugnoli, L. Alberto, Pharmacological differences and clinical 
implications of various botulinum toxin preparations: a critical appraisal, Funct Neurol, 33 (2018) 
7-18. 
[9] B. Peyronnet, B.M. Brucker, M.C. Michel, Lower Urinary Tract Symptoms: What's New in 
Medical Treatment?, Eur Urol Focus, 4 (2018) 17-24. 
[10] M. Field, A. Splevins, P. Picaut, M. van der Schans, J. Langenberg, D. Noort, D. Snyder, K. 
Foster, AbobotulinumtoxinA (Dysport((R))), OnabotulinumtoxinA (Botox((R))), and 
IncobotulinumtoxinA (Xeomin((R))) Neurotoxin Content and Potential Implications for Duration 
of Response in Patients, Toxins, 10 (2018). 
[11] M.F. Brin, C. James, J. Maltman, Botulinum toxin type A products are not interchangeable: 
a review of the evidence, Biologics, 8 (2014) 227-241. 
[12] F. Cruz, Targets for botulinum toxin in the lower urinary tract, Neurourology and 
urodynamics, 33 (2014) 31-38. 
[13] F. Cruz, V. Nitti, Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and 
overactive bladder (OAB), Neurourology and urodynamics, 33 Suppl 3 (2014) S26-31. 
[14] E. Fernandez-Salas, J. Wang, Y. Molina, J.B. Nelson, B.P. Jacky, K.R. Aoki, Botulinum 
neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay, PloS 
one, 7 (2012) e49516. 
125
  
[15] A. Kutschenko, A. Manig, M.C. Reinert, A. Monnich, D. Liebetanz, In-vivo comparison of the 
neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA, 
Neurosci Lett, 627 (2016) 216-221. 
[16] A. Marchetti, R. Magar, L. Findley, J.P. Larsen, Z. Pirtosek, E. Ruzicka, R. Jech, J. Slawek, F. 
Ahmed, Retrospective evaluation of the dose of Dysport and BOTOX in the management of 
cervical dystonia and blepharospasm: the REAL DOSE study, Movement disorders : official 
journal of the Movement Disorder Society, 20 (2005) 937-944. 
[17] P. Ravindra, B.L. Jackson, R.J. Parkinson, Botulinum toxin type A for the treatment of non-
neurogenic overactive bladder: does using onabotulinumtoxinA (Botox((R)) ) or 
abobotulinumtoxinA (Dysport((R)) ) make a difference?, BJU international, 112 (2013) 94-99. 
[18] A. Mangera, K.E. Andersson, A. Apostolidis, C. Chapple, P. Dasgupta, A. Giannantoni, S. 
Gravas, S. Madersbacher, Contemporary management of lower urinary tract disease with 
botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport 
(abobotulinumtoxinA), European urology, 60 (2011) 784-795. 
[19] M. Naumann, L.M. Boo, A.H. Ackerman, C.J. Gallagher, Immunogenicity of botulinum toxins, 
J Neural Transm (Vienna), 120 (2013) 275-290. 
[20] L. Carli, C. Montecucco, O. Rossetto, Assay of diffusion of different botulinum neurotoxin 
type a formulations injected in the mouse leg, Muscle Nerve, 40 (2009) 374-380. 
[21] M. Pirazzini, O. Rossetto, R. Eleopra, C. Montecucco, Botulinum Neurotoxins: Biology, 
Pharmacology, and Toxicology, Pharmacol Rev, 69 (2017) 200-235. 
[22] L.F. Cooley, S. Kielb, A Review of Botulinum Toxin A for the Treatment of Neurogenic 
Bladder, PM R, 11 (2019) 192-200. 
[23] J. Jankovic, Botulinum toxin: State of the art, Movement disorders : official journal of the 
Movement Disorder Society, 32 (2017) 1131-1138. 
[24] B. Schurch, D.M. Schmid, M. Stohrer, Treatment of neurogenic incontinence with botulinum 
toxin A, The New England journal of medicine, 342 (2000) 665. 
[25] B. Schurch, M. Stohrer, G. Kramer, D.M. Schmid, G. Gaul, D. Hauri, Botulinum-A toxin for 
treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to 
anticholinergic drugs? Preliminary results, The Journal of urology, 164 (2000) 692-697. 
[26] A. Giannantoni, E. Mearini, M. Del Zingaro, M. Porena, Six-year follow-up of botulinum toxin 
A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical 
and urodynamic results, European urology, 55 (2009) 705-711. 
[27] J. Pannek, K. Gocking, U. Bersch, Long-term effects of repeated intradetrusor botulinum 
neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction, 
BJU international, 104 (2009) 1246-1250. 
[28] F. Cruz, S. Herschorn, P. Aliotta, M. Brin, C. Thompson, W. Lam, G. Daniell, J. Heesakkers, C. 
Haag-Molkenteller, Efficacy and safety of onabotulinumtoxinA in patients with urinary 
126
  
incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-
controlled trial, European urology, 60 (2011) 742-750. 
[29] B. Schurch, P. Denys, C.M. Kozma, P.R. Reese, T. Slaton, R.L. Barron, Botulinum toxin A 
improves the quality of life of patients with neurogenic urinary incontinence, European urology, 
52 (2007) 850-858. 
[30] G.P. Li, X.Y. Wang, Y. Zhang, Efficacy and Safety of OnabotulinumtoxinA in Patients With 
Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-
analysis, Int Neurourol J, 22 (2018) 275-286. 
[31] A. Coelho, F. Cruz, C.D. Cruz, A. Avelino, Spread of onabotulinumtoxinA after bladder 
injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the 
toxin action, European urology, 61 (2012) 1178-1184. 
[32] A. Coelho, P. Dinis, R. Pinto, T. Gorgal, C. Silva, A. Silva, J. Silva, C.D. Cruz, F. Cruz, A. Avelino, 
Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in 
the human bladder, European urology, 57 (2010) 884-890. 
[33] R. Oliveira, A. Coelho, A. Charrua, A. Avelino, F. Cruz, Expression of cleaved SNAP-25 after 
bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: A comparative study in 
the mice, Neurourology and urodynamics, 36 (2017) 86-90. 
[34] C.J. Fowler, D. Griffiths, W.C. de Groat, The neural control of micturition, Nature reviews. 
Neuroscience, 9 (2008) 453-466. 
[35] L.A. Birder, Urothelial signaling, Autonomic neuroscience : basic & clinical, 153 (2010) 33-
40. 
[36] L.A. Birder, Y. Nakamura, S. Kiss, M.L. Nealen, S. Barrick, A.J. Kanai, E. Wang, G. Ruiz, W.C. 
De Groat, G. Apodaca, S. Watkins, M.J. Caterina, Altered urinary bladder function in mice lacking 
the vanilloid receptor TRPV1, Nat Neurosci, 5 (2002) 856-860. 
[37] A. Charrua, C. Reguenga, J.M. Cordeiro, P. Correiade-Sa, C. Paule, I. Nagy, F. Cruz, A. Avelino, 
Functional transient receptor potential vanilloid 1 is expressed in human urothelial cells, The 
Journal of urology, 182 (2009) 2944-2950. 
[38] W.C. de Groat, M. Kawatani, T. Hisamitsu, C.L. Cheng, C.P. Ma, K. Thor, W. Steers, J.R. 
Roppolo, Mechanisms underlying the recovery of urinary bladder function following spinal cord 
injury, Journal of the autonomic nervous system, 30 Suppl (1990) S71-77. 
[39] A. Coelho, R. Oliveira, O. Rossetto, C.D. Cruz, F. Cruz, A. Avelino, Intrathecal administration 
of botulinum toxin type A improves urinary bladder function and reduces pain in rats with 
cystitis, European journal of pain (London, England), 18 (2014) 1480-1489. 
[40] B. Frias, J. Santos, M. Morgado, M.M. Sousa, S.M. Gray, K.D. McCloskey, S. Allen, F. Cruz, 
C.D. Cruz, The role of brain-derived neurotrophic factor (BDNF) in the development of 
neurogenic detrusor overactivity (NDO), The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 35 (2015) 2146-2160. 
127
  
[41] N.D. Zinck, V.F. Rafuse, J.W. Downie, Sprouting of CGRP primary afferents in lumbosacral 
spinal cord precedes emergence of bladder activity after spinal injury, Experimental neurology, 
204 (2007) 777-790. 
[42] Y. Ikeda, I.V. Zabbarova, L.A. Birder, W.C. de Groat, C.J. McCarthy, A.T. Hanna-Mitchell, A.J. 
Kanai, Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as 
well as efferent nerves in the urinary bladder, European urology, 62 (2012) 1157-1164. 
[43] K.D. Anderson, Targeting recovery: priorities of the spinal cord-injured population, Journal 
of neurotrauma, 21 (2004) 1371-1383. 
[44] C.W. Liu, C.C. Huang, Y.H. Yang, S.C. Chen, M.C. Weng, M.H. Huang, Relationship between 
neurogenic bowel dysfunction and health-related quality of life in persons with spinal cord 
injury, J Rehabil Med, 41 (2009) 35-40. 
[45] J.J. van Middendorp, H.C. Allison, S. Ahuja, D. Bracher, C. Dyson, J. Fairbank, A. Gall, A. 
Glover, L. Gray, W.E. Masri, A. Uttridge, K. Cowan, Top ten research priorities for spinal cord 
injury: the methodology and results of a British priority setting partnership, Spinal cord, 54 
(2016) 341-346. 
[46] J.N. Panicker, C.J. Fowler, T.M. Kessler, Lower urinary tract dysfunction in the neurological 
patient: clinical assessment and management, The Lancet. Neurology, 14 (2015) 720-732. 
[47] H.Z. Hu, N. Granger, N.D. Jeffery, Pathophysiology, Clinical Importance, and Management 
of Neurogenic Lower Urinary Tract Dysfunction Caused by Suprasacral Spinal Cord Injury, Journal 
of veterinary internal medicine / American College of Veterinary Internal Medicine, 30 (2016) 
1575-1588. 
[48] K.D. Sievert, B. Amend, G. Gakis, P. Toomey, A. Badke, H.P. Kaps, A. Stenzl, Early sacral 
neuromodulation prevents urinary incontinence after complete spinal cord injury, Annals of 
neurology, 67 (2010) 74-84. 
[49] P. Li, L. Liao, G. Chen, F. Zhang, Y. Tian, Early low-frequency stimulation of the pudendal 
nerve can inhibit detrusor overactivity and delay progress of bladder fibrosis in dogs with spinal 
cord injuries, Spinal cord, 51 (2013) 668-672. 
[50] X. Biardeau, M. Przydacz, S. Aharony, G. Loutochin, L. Campeau, M. Kyheng, J. Corcos, Early 
Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal 
Cord Transected Rat Model, PloS one, 12 (2017) e0169694. 
[51] F.A. Salinas, L.H. Lugo, H.I. Garcia, Efficacy of early treatment with carbamazepine in 
prevention of neuropathic pain in patients with spinal cord injury, Am J Phys Med Rehabil, 91 
(2012) 1020-1027. 
[52] B. Francois, P. Vacher, J. Roustan, J.Y. Salle, J. Vidal, J.J. Moreau, P. Vignon, Intrathecal 
baclofen after traumatic brain injury: early treatment using a new technique to prevent 
spasticity, J Trauma, 50 (2001) 158-161. 
[53] D. Behr-Roussel, S. Oger, B. Pignol, E. Pham, A. Le Maux, P.E. Chabrier, S. Caisey, S. 
Compagnie, P. Picaut, J. Bernabe, L. Alexandre, F. Giuliano, P. Denys, Minimal effective dose of 
128
  
dysport and botox in a rat model of neurogenic detrusor overactivity, European urology, 61 
(2012) 1054-1061. 
[54] G. Temeltas, C. Tikiz, T. Dagci, I. Tuglu, A. Yavasoglu, The effects of botulinum-A toxin on 
bladder function and histology in spinal cord injured rats: is there any difference between early 
and late application?, The Journal of urology, 174 (2005) 2393-2396. 
[55] W.C. de Groat, N. Yoshimura, Mechanisms underlying the recovery of lower urinary tract 
function following spinal cord injury, Progress in brain research, 152 (2006) 59-84. 
[56] W.C. de Groat, N. Yoshimura, Afferent nerve regulation of bladder function in health and 
disease, Handb Exp Pharmacol, DOI 10.1007/978-3-540-79090-7_4(2009) 91-138. 
[57] A. Avelino, C. Cruz, I. Nagy, F. Cruz, Vanilloid receptor 1 expression in the rat urinary tract, 
Neuroscience, 109 (2002) 787-798. 
[58] C.M. Brady, A.N. Apostolidis, M. Harper, Y. Yiangou, A. Beckett, T.S. Jacques, A. Freeman, F. 
Scaravilli, C.J. Fowler, P. Anand, Parallel changes in bladder suburothelial vanilloid receptor 
TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor 
overactivity after intravesical resiniferatoxin treatment, BJU international, 93 (2004) 770-776. 
[59] A. Apostolidis, C.M. Brady, Y. Yiangou, J. Davis, C.J. Fowler, P. Anand, Capsaicin receptor 
TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin, 
Urology, 65 (2005) 400-405. 
[60] R.M. Craft, S.M. Cohen, F. Porreca, Long-lasting desensitization of bladder afferents 
following intravesical resiniferatoxin and capsaicin in the rat, Pain, 61 (1995) 317-323. 
[61] C. Silva, M.E. Rio, F. Cruz, Desensitization of bladder sensory fibers by intravesical 
resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia, 
European urology, 38 (2000) 444-452. 
[62] C. Silva, J. Silva, M.J. Ribeiro, A. Avelino, F. Cruz, Urodynamic effect of intravesical 
resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a 
double-blind randomized placebo-controlled trial, European urology, 48 (2005) 650-655. 
[63] M. Lazzeri, M. Spinelli, P. Beneforti, A. Zanollo, D. Turini, Intravesical resiniferatoxin for the 
treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord 
diseases, Scand J Urol Nephrol, 32 (1998) 331-334. 
[64] A. Giannantoni, E. Mearini, S.M. Di Stasi, E. Costantini, A. Zucchi, L. Mearini, P. Fornetti, M. 
Del Zingaro, P. Navarra, M. Porena, New therapeutic options for refractory neurogenic detrusor 
overactivity, Minerva Urol Nefrol, 56 (2004) 79-87. 
[65] C.B. Shoemaker, G.A. Oyler, Persistence of Botulinum neurotoxin inactivation of nerve 
function, Curr Top Microbiol Immunol, 364 (2013) 179-196. 
 
 
129
  
 
 
130
